| Year |
Citation |
Score |
| 2024 |
Lin A, Pearl N, Flynn J, Devlin S, Dahi P, Perales MA, Scordo M, Shah GL. Influence of Obesity on the Efficacy and Toxicity of Patients Undergoing Autologous Hematopoietic Cell Transplantation for Lymphoma. Clinical Lymphoma, Myeloma & Leukemia. PMID 39343716 DOI: 10.1016/j.clml.2024.09.003 |
0.364 |
|
| 2024 |
Shaffer BC, Brown S, Chinapen S, Mangold K, Lahoud OB, Lopez-Jimenez F, Schaffer WL, Liu JE, Giralt SA, Devlin SM, Shah GL, Scordo M, Papadopoulos EB, Landau HJ, Usmani SZ, et al. Artificial Intelligence Enabled Interpretation of ECG Images to Predict Hematopoietic Cell Transplantation Toxicity. Blood Advances. PMID 39158065 DOI: 10.1182/bloodadvances.2024013636 |
0.354 |
|
| 2024 |
Costa BA, Flynn J, Nishimura N, Devlin SM, Farzana T, Rajeeve S, Chung DJ, Landau HJ, Lahoud OB, Scordo M, Shah GL, Hassoun H, Maclachlan K, Hultcrantz M, Korde N, et al. Prognostic impact of corticosteroid and tocilizumab use following chimeric antigen receptor T-cell therapy for multiple myeloma. Blood Cancer Journal. 14: 84. PMID 38802346 DOI: 10.1038/s41408-024-01048-0 |
0.303 |
|
| 2024 |
Stuver R, Mian A, Brown S, Devlin S, Caimi PF, Chinapen S, Dahi P, Dean R, Epstein-Peterson ZD, Hill B, Horwitz SM, Lahoud O, Lin R, Moskowitz AJ, Sauter C, et al. BEAM versus pharmacokinetics-directed BuCyVP16 conditioning for patients with peripheral T-cell lymphoma undergoing high-dose therapy with autologous hematopoietic cell transplantation. American Journal of Hematology. PMID 38526002 DOI: 10.1002/ajh.27291 |
0.338 |
|
| 2024 |
Fingrut WB, Davis E, Archer A, Brown S, Devlin SM, Nhaissi M, Rapoport C, Chinapen S, Kelly A, Wells DS, Scaradavou A, Gyurkocza B, Papadopoulos EB, Politikos I, Shaffer BC, et al. Racial/ ethnic disparities in availability of volunteer unrelated donors for allogeneic transplantation. Blood Advances. PMID 38429097 DOI: 10.1182/bloodadvances.2023012385 |
0.315 |
|
| 2023 |
Infante MS, Nemirovsky D, Devlin S, DeWolf S, Tamari R, Dahi PB, Lee YJ, Chung DJ, Politikos I, Barker J, Giralt SA, Babady NE, Ramanathan L, Papanicolaou GA, Seo S, et al. Outcomes and Management of SARS-CoV2 Omicron Variant in Recipients of Hematopoietic Cell Transplantation (HCT) and Chimeric Antigen Receptor T cell (CART) therapy. Transplantation and Cellular Therapy. PMID 37806446 DOI: 10.1016/j.jtct.2023.09.027 |
0.327 |
|
| 2023 |
Nath K, Peterson K, Brown S, Devlin S, Rodriguez N, Barker J, Giralt S, Gyurkocza B, Jakubowski A, Papadopoulos E, Ponce D, Scordo M, Shah G, Perales MA, Sauter C, et al. Reduced-Intensity Compared to Nonmyeloablative Conditioning in Patients with Non-Hodgkin Lymphoma Undergoing Allogeneic Hematopoietic Stem Cell Transplantation. Transplantation and Cellular Therapy. PMID 37788792 DOI: 10.1016/j.jtct.2023.09.022 |
0.4 |
|
| 2023 |
Dahi PB, Kenny S, Flynn J, Devlin SM, Ruiz JD, Chinapen SA, Lahoud OB, Matasar MJ, Moskowitz CH, Perales MA, Shah G, Sauter CS, Giralt SA, Geyer AI, Jakubowski AA. Utility of routine pulmonary function test after autologous hematopoietic cell transplantation in lymphoma. Leukemia & Lymphoma. 1-7. PMID 37690007 DOI: 10.1080/10428194.2023.2256912 |
0.322 |
|
| 2023 |
Nath K, Lee J, Elko TA, Levy L, Preston E, Devlin SM, Ponce DM, Lin RJ, Shaffer BC, Cho C, Politikos I, Jakubowski AA, Park JH, Rampal R, Perales MA, et al. Prospective analysis to determine barriers to allogeneic hematopoietic cell transplantation in patients with acute leukemia. American Journal of Hematology. PMID 37688521 DOI: 10.1002/ajh.27084 |
0.417 |
|
| 2023 |
Elias S, Brown S, Devlin SM, Barker JN, Cho C, Chung DJ, Dahi PB, Giralt S, Gyurkocza B, Jakubowski AA, Lahoud OB, Landau H, Lin RJ, Papadopoulos EB, Politikos I, et al. The Simplified Comorbidity Index predicts non-relapse mortality in reduced-intensity conditioning allogeneic haematopoietic cell transplantation. British Journal of Haematology. PMID 37614192 DOI: 10.1111/bjh.19055 |
0.369 |
|
| 2023 |
Cho C, Devlin S, Maloy M, Horowitz MM, Logan B, Rizzo JD, Giralt SA, Perales MA. Application of the CIBMTR One Year Survival Outcomes Calculator as a tool for retrospective analysis. Bone Marrow Transplantation. PMID 37422574 DOI: 10.1038/s41409-023-02031-2 |
0.326 |
|
| 2023 |
Sanchez-Escamilla M, Flynn J, Devlin S, Maloy M, Fatmi SA, Tomas AA, Escribano-Serrat S, Ponce D, Sauter CS, Giralt SA, Scordo M, Perales MA. EASIX score predicts inferior survival after allogeneic hematopoietic cell transplantation. Bone Marrow Transplantation. PMID 36721042 DOI: 10.1038/s41409-023-01922-8 |
0.352 |
|
| 2022 |
Wudhikarn K, Alarcon Tomas A, Flynn JR, Devlin SM, Brower J, Bachanova V, Nastoupil LJ, McGuirk JP, Maziarz RT, Oluwole OO, Schuster SJ, Porter DL, Bishop MR, Riedell PA, Perales MA. Low toxicity and excellent outcomes in patients with DLBCL without residual lymphoma at the time of CD19 CAR T-cell therapy. Blood Advances. PMID 36355838 DOI: 10.1182/bloodadvances.2022008294 |
0.301 |
|
| 2022 |
Fried S, Shouval R, Walji M, Flynn JR, Yerushalmi R, Shem-Tov N, Danylesko I, Tomas AA, Fein JA, Devlin SM, Sauter CS, Shah GL, Kedmi M, Jacoby E, Shargian L, et al. Allogeneic Hematopoietic Cell Transplantation after Chimeric Antigen Receptor T Cell Therapy in Large B Cell Lymphoma. Transplantation and Cellular Therapy. PMID 36343892 DOI: 10.1016/j.jtct.2022.10.026 |
0.386 |
|
| 2022 |
Shouval R, Waters NR, Gomes ALC, Zuanelli Brambilla C, Fei T, Devlin SM, Nguyen CL, Markey KA, Dai A, Slingerland JB, Clurman AG, Fontana E, Amoretti LA, Wright RJ, Hohl TM, et al. Conditioning regimens are associated with distinct patterns of microbiota injury in allogeneic hematopoietic cell transplantation. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 36322005 DOI: 10.1158/1078-0432.CCR-22-1254 |
0.327 |
|
| 2022 |
Stahl M, Derkach A, Farnoud N, Bewersdorf JP, Robinson T, Famulare C, Cho C, Devlin S, Menghrajani K, Patel MA, Cai SF, Miles LA, Bowman RL, Geyer MB, Dunbar A, et al. Molecular predictors of immunophenotypic measurable residual disease clearance in acute myeloid leukemia. American Journal of Hematology. PMID 36251406 DOI: 10.1002/ajh.26757 |
0.355 |
|
| 2022 |
Fingrut WB, Gyurkocza B, Flynn JR, Davis E, Devlin SM, Scaradavou A, Chinapen S, Quach S, Cho C, Giralt SA, Jakubowski AA, Lin RJ, Papadopoulos EB, Perales MA, Ponce DM, et al. Analysis of Disparities in Time to Allogeneic Transplantation in Adults with Acute Myelogenous Leukemia. Blood Advances. PMID 36240477 DOI: 10.1182/bloodadvances.2022008572 |
0.39 |
|
| 2022 |
Landau HJ, Orlando E, Rodriguez ES, Applebaum A, Mitchell HR, Peled JU, Khan N, Funnell T, Chung D, Scordo M, Shah GL, LeStrange NJ, Hambright KA, McElrath CM, Cazeau N, ... Devlin SM, et al. Pilot Trial of Homebound Hematopoietic Cell Transplantation. Transplantation and Cellular Therapy. PMID 36182105 DOI: 10.1016/j.jtct.2022.09.014 |
0.38 |
|
| 2022 |
Scordo M, Shah GL, Adintori PA, Knezevic A, Devlin SM, Buchan ML, Preston EV, Lin AP, Rodriguez NT, Carino CA, Nguyen LK, Sitner NC, Barasch A, Klang MG, Maloy MA, et al. A prospective study of dysgeusia and related symptoms in patients with multiple myeloma after autologous hematopoietic cell transplantation. Cancer. PMID 36041227 DOI: 10.1002/cncr.34444 |
0.367 |
|
| 2022 |
Nawas MT, Sanchez-Escamilla M, Devlin SM, Maloy M, Ruiz JD, Sauter CS, Giralt SA, Perales MA, Scordo M. Dynamic EASIX Scores Closely Predict Nonrelapse Mortality After Allogeneic Hematopoietic Cell Transplantation. Blood Advances. PMID 35977079 DOI: 10.1182/bloodadvances.2022007381 |
0.36 |
|
| 2022 |
Burgos da Silva M, Ponce DM, Dai A, Devlin SM, Gomes AL, Moore GF, Slingerland J, Shouval R, Armijo GK, DeWolf S, Fei T, Clurman A, Fontana E, Amoretti LA, Wright RJ, et al. Preservation of fecal microbiome is associated with reduced severity of Graft-versus-Host Disease. Blood. PMID 35969834 DOI: 10.1182/blood.2021015352 |
0.336 |
|
| 2022 |
Politikos I, Lau C, Devlin SM, Quach S, Lin A, Perales MA, Shah GL, Seo S, Papanicolaou G, Barker JN. Extended Duration Letermovir Prophylaxis for Cytomegalovirus Infection after Cord Blood Transplantation in Adults. Blood Advances. PMID 35802462 DOI: 10.1182/bloodadvances.2022008047 |
0.317 |
|
| 2022 |
Jimenez Jimenez AM, Komanduri K, Brown S, Wang TP, Pereira DL, Goodman M, Beitinjaneh A, Lekakis LJ, Chinapen S, Devlin SM, Ponce DM, Sauter CS, Perales MA, Shaffer BC. Improved GRFS after posttransplant cyclophosphamide-based vs ATG-based HLA-mismatched unrelated donor transplant. Blood Advances. PMID 35793451 DOI: 10.1182/bloodadvances.2022007596 |
0.384 |
|
| 2022 |
Lahoud OB, Landau H, Nguyen J, Devlin S, Lendvai N, Weltz J, Ayorinde T, Chung DJ, Lesokhin AM, Kewalramani T, Korde N, Mailankody S, Landgren O, Giralt S, Comenzo RL, et al. Continuous induction with lenalidomide/dexamethasone versus autologous stem cell transplantation in newly diagnosed multiple myeloma: a case for response-adapted approach. Leukemia & Lymphoma. 1-10. PMID 35648041 DOI: 10.1080/10428194.2022.2062347 |
0.387 |
|
| 2022 |
Andrlová H, Miltiadous O, Kousa AI, Dai A, DeWolf S, Violante S, Park HY, Janaki-Raman S, Gardner R, El Daker S, Slingerland J, Giardina P, Clurman A, Gomes ALC, Nguyen C, ... ... Devlin SM, et al. MAIT and Vδ2 unconventional T cells are supported by a diverse intestinal microbiome and correlate with favorable patient outcome after allogeneic HCT. Science Translational Medicine. 14: eabj2829. PMID 35613281 DOI: 10.1126/scitranslmed.abj2829 |
0.318 |
|
| 2022 |
Nawas MT, Lee JO, Flynn J, Maloy M, Jakubowski AA, Papadopoulos EB, Cho C, Ponce DM, Sauter CS, Perales MA, Devlin S, Giralt SA, Castro-Malaspina HR, Tamari R. CD34+ -selected hematopoietic stem cell transplant conditioned with a myeloablative regimen in patients with advanced myelofibrosis. Bone Marrow Transplantation. PMID 35484207 DOI: 10.1038/s41409-022-01684-9 |
0.441 |
|
| 2022 |
Sola M, Bhatt V, Palazzo M, Cavalier KE, Devlin SM, Maloy M, Barker JN, Castro-Malaspina H, Chung D, Dahi PB, Jakubowski AA, Landau H, Papadopoulos EB, Perales MA, Sauter C, et al. Low-dose unfractionated heparin prophylaxis is a safe strategy for the prevention of hepatic sinusoidal obstruction syndrome after myeloablative adult allogenic stem cell transplant. Bone Marrow Transplantation. PMID 35477992 DOI: 10.1038/s41409-022-01689-4 |
0.374 |
|
| 2022 |
Smith M, Dai A, Ghilardi G, Amelsberg KV, Devlin SM, Pajarillo R, Slingerland JB, Beghi S, Herrera PS, Giardina P, Clurman A, Dwomoh E, Armijo G, Gomes ALC, Littmann ER, et al. Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy. Nature Medicine. PMID 35288695 DOI: 10.1038/s41591-022-01702-9 |
0.314 |
|
| 2022 |
Lin A, Brown S, Maloy M, Ruiz JD, Devlin S, DeRespiris L, Proli A, Jakubowski AA, Papadopoulos EB, Sauter CS, Tamari R, Castro-Malaspina H, Shaffer B, Barker J, Perales MA, et al. Impact of omitting post-transplant minidose-methotrexate doses in allogeneic hematopoietic cell transplantation. Leukemia & Lymphoma. 1-8. PMID 35142567 DOI: 10.1080/10428194.2022.2032036 |
0.357 |
|
| 2022 |
Miltiadous O, Waters NR, Andrlova H, Dai A, Nguyen CL, Burgos da Silva M, Lindner S, Slingerland J, Giardina P, Clurman A, Armijo GK, Gomes AL, Lakkaraja M, Maslak PG, Scordo M, ... ... Devlin SM, et al. Early intestinal microbial features are associated with CD4 T cell recovery after allogeneic hematopoietic transplant. Blood. PMID 35061893 DOI: 10.1182/blood.2021014255 |
0.333 |
|
| 2021 |
Shouval R, Fein JA, Cho C, Avecilla S, Ruiz JD, Alarcon Tomas A, Sanchez-Escamilla M, Castillo Flores N, Yanez San Segundo L, Barker JN, Dahi PB, Giralt S, Geyer A, Gyurkocza B, Jakubowski AA, ... ... Devlin SM, et al. The Simplified Comorbidity Index (SCI) - a new tool for prediction of non-relapse mortality in allogeneic HCT. Blood Advances. PMID 34507354 DOI: 10.1182/bloodadvances.2021004319 |
0.373 |
|
| 2021 |
Lahoud OB, Devlin SM, Maloy MA, Roeker LE, Dahi PB, Ponce DM, Gyurkocza B, Koehne G, Young JW, Castro-Malaspina HR, Barker JN, Papadopoulos EB, Jakubowski AA, Zelenetz AD, Mato AR, et al. Reduced-intensity conditioning hematopoietic stem cell transplantation for chronic lymphocytic leukemia and Richter's transformation. Blood Advances. 5: 2879-2889. PMID 34297048 DOI: 10.1182/bloodadvances.2020003726 |
0.411 |
|
| 2021 |
Alarcon Tomas A, Whiting K, Maloy M, Ruiz JD, Devlin S, Sanchez-Escamilla M, Yañez L, Castillo N, Pennisi M, Cho C, Shaffer B, Castro-Malaspina H, Klimek V, Giralt SA, Tamari R, et al. The post-transplant scoring system (PTSS) is associated with outcomes in patients with MDS after CD34+selected allogeneic stem cell transplant. Bone Marrow Transplantation. PMID 34253878 DOI: 10.1038/s41409-021-01392-w |
0.418 |
|
| 2021 |
Tamari R, Brown S, Devlin SM, Kosuri S, Maloy MA, Ponce DM, Sauter C, Shaffer B, Dahi P, Young JW, Jakubowski A, Papadopoulos EB, Castro-Malaspina H, Perales MA, Giralt SA, et al. Fractionated Infusion of Hematopoietic Progenitor Cells Does Not Improve Neutrophil Recovery or Survival in Allograft Recipients. Transplantation and Cellular Therapy. PMID 34214736 DOI: 10.1016/j.jtct.2021.06.022 |
0.381 |
|
| 2021 |
Dahi PB, Lee J, Devlin SM, Ruiz J, Maloy M, Rondon-Clavo C, Petrlik E, Tamari R, Shah G, Scordo M, Matasar MJ, Hamlin PA, Papadopoulos E, Jakubowski AA, Perales MA, et al. Toxicities of high-dose chemotherapy and autologous hematopoietic cell transplantation in older patients with lymphoma. Blood Advances. 5: 2608-2618. PMID 34152404 DOI: 10.1182/bloodadvances.2020004167 |
0.357 |
|
| 2021 |
Brambilla CZ, Lobaugh SM, Ruiz JD, Dahi PB, Goldberg AD, Young JW, Gyurkocza B, Shaffer BC, Ponce DM, Tamari R, Escamilla MS, Flores NC, Politikos I, Scordo M, Shah GL, ... ... Devlin SM, et al. Relapse after allogeneic stem cell transplantation of acute myeloid leukemia and myelodysplastic syndrome and importance of second cellular therapy. Transplantation and Cellular Therapy. PMID 34033977 DOI: 10.1016/j.jtct.2021.05.011 |
0.371 |
|
| 2021 |
Rodriguez N, Lee J, Flynn L, Murray F, Devlin SM, Soto C, Cho C, Dahi P, Giralt S, Perales MA, Sauter C, Ponce DM. Oral Proteasome Inhibitor Ixazomib for Switch-Maintenance Prophylaxis of Recurrent or Late Acute and Chronic Graft-versus-Host Disease after Day 100 in Allogeneic Stem Cell Transplantation. Transplantation and Cellular Therapy. PMID 34029766 DOI: 10.1016/j.jtct.2021.05.008 |
0.335 |
|
| 2021 |
Jacob RP, Flynn J, Devlin SM, Maloy M, Giralt SA, Maslak P, O'Reilly RJ, Tonon JA, Perales MA, Avecilla ST, Cho C. Universal Engraftment after Allogeneic Hematopoietic Cell Transplantation Using Cryopreserved CD34 Selected Grafts. Transplantation and Cellular Therapy. PMID 33991721 DOI: 10.1016/j.jtct.2021.04.026 |
0.325 |
|
| 2021 |
Shaffer BC, Le Luduec JB, Park S, Devlin S, Archer A, Davis E, Cooper C, Nhaissi M, Suri B, Wells D, Tamari R, Papadopoulos E, Jakubowski AA, Giralt S, Hsu KC. Prospective KIR genotype evaluation of hematopoietic cell donors is feasible with potential to benefit patients with AML. Blood Advances. 5: 2003-2011. PMID 33843984 DOI: 10.1182/bloodadvances.2020002701 |
0.384 |
|
| 2021 |
Garcia-Recio M, Wudhikarn K, Pennisi M, Alonso-Trillo R, Flynn J, Shouval R, Afuye AO, Silverberg ML, Batlevi CW, Dahi P, Devlin S, Giralt SA, Halton E, Ruiz J, Maloy M, et al. The International Prognostic Index Is Associated with Outcomes in Diffuse Large B Cell Lymphoma after Chimeric Antigen Receptor T Cell Therapy. Transplantation and Cellular Therapy. 27: 233-240. PMID 33781518 DOI: 10.1016/j.jtct.2020.10.022 |
0.35 |
|
| 2021 |
Miltiadous O, Andrlova H, Dai A, Nguyen C, da Silva MB, Gomes A, Lindner S, Slingerland J, Giardina P, Clurman A, Armijo GK, Lakkaraja M, Scordo M, O’Reilly RJ, Prockop SE, ... ... Devlin SM, et al. Intestinal Microbiota Composition and Diversity Are Associated with CD4 T Cell Reconstitution after Allogeneic Hematopoietic Cell Transplantation Transplantation and Cellular Therapy. 27: S92-S93. DOI: 10.1016/S2666-6367(21)00122-6 |
0.302 |
|
| 2021 |
Rodriguez NT, Lee J, Flynn L, Murray F, Devlin SM, Soto C, Cho C, Dahi PB, Giralt SA, Perales M, Sauter CS, Ponce DM. Secondary Graft-Versus-Host Disease (GVHD) Prophylaxis with Oral Proteasome Inhibitor Ixazomib Is Associated with Low Incidence of Recurrent, Late Acute and Chronic GVHD and Facilitated Calcineurin Inhibitor Taper within the First Year Post Allogeneic Stem Cell Transplantation Transplantation and Cellular Therapy. 27: S80-S81. DOI: 10.1016/S2666-6367(21)00110-X |
0.331 |
|
| 2021 |
Shouval R, Fein JA, Cho C, Avecilla ST, Ruiz JD, Sanchez-Escamilla M, Tomas AA, Flores NC, San Segundo LY, Barker JN, Dahi PB, Giralt SA, Geyer A, Gyurkocza B, Jakubowski AA, ... ... Devlin SM, et al. A Simplified Comorbidity Index Predicts Mortality in Allogeneic Hematopoietic Stem Cell Transplantation Recipients Transplantation and Cellular Therapy. 27: S23-S24. DOI: 10.1016/S2666-6367(21)00051-8 |
0.327 |
|
| 2020 |
Khan N, Lindner S, Gomes AL, Devlin SM, Shah G, Sung AD, Sauter CS, Landau H, Dahi PB, Perales MA, Chung D, Lesokhin AM, Dai A, Clurman A, Slingerland J, et al. Fecal microbiota diversity disruption and clinical outcomes after auto-HCT: a multicenter observational study. Blood. PMID 33512409 DOI: 10.1182/blood.2020006923 |
0.387 |
|
| 2020 |
Barker JN, Devlin SM, Naputo KA, Skinner K, Maloy MA, Flynn L, Anagnostou T, Avecilla ST, Scaradavou A, Cho C, Dahi PB, Giralt SA, Gyurkocza B, Hanash AM, Hsu K, et al. High progression-free survival after intermediate intensity double unit cord blood transplantation in adults. Blood Advances. 4: 6064-6076. PMID 33290545 DOI: 10.1182/bloodadvances.2020003371 |
0.421 |
|
| 2020 |
Menghrajani K, Zhang Y, Famulare C, Devlin SM, Tallman MS. Acute myeloid leukemia with 11q23 rearrangements: A study of therapy-related disease and therapeutic outcomes. Leukemia Research. 98: 106453. PMID 33059120 DOI: 10.1016/j.leukres.2020.106453 |
0.317 |
|
| 2020 |
Lin A, Flynn J, DeRespiris L, Figgins B, Griffin M, Lau C, Proli A, Devlin SM, Cho C, Tamari R, Jakubowski AA, Papadopoulos EB, Giralt SA, Perales MA, Seo SK, et al. Letermovir for prevention of cytomegalovirus reactivation in haploidentical and mismatched adult donor allogeneic hematopoietic cell transplantation with post-transplant cyclophosphamide for graft-versus-host disease prophylaxis. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. PMID 33053449 DOI: 10.1016/j.bbmt.2020.10.009 |
0.374 |
|
| 2020 |
Shah GL, DeWolf S, Lee YJ, Tamari R, Dahi PB, Lavery JA, Ruiz JD, Devlin SM, Cho C, Peled JU, Politikos I, Scordo M, Babady NE, Jain T, Vardhana S, et al. Favorable outcomes of COVID-19 in recipients of hematopoietic cell transplantation. The Journal of Clinical Investigation. PMID 32897885 DOI: 10.1172/Jci141777 |
0.447 |
|
| 2020 |
Jain T, Knezevic A, Pennisi M, Chen Y, Ruiz JD, Purdon TJ, Devlin SM, Smith M, Shah GL, Halton E, Diamonte C, Scordo M, Sauter CS, Mead E, Santomasso BD, et al. Hematopoietic recovery in patients receiving chimeric antigen receptor T-cell therapy for hematologic malignancies. Blood Advances. 4: 3776-3787. PMID 32780846 DOI: 10.1182/Bloodadvances.2020002509 |
0.417 |
|
| 2020 |
Wudhikarn K, Palomba ML, Pennisi M, Garcia-Recio M, Flynn JR, Devlin SM, Afuye A, Silverberg ML, Maloy MA, Shah GL, Scordo M, Dahi PB, Sauter CS, Batlevi CL, Santomasso BD, et al. Infection during the first year in patients treated with CD19 CAR T cells for diffuse large B cell lymphoma. Blood Cancer Journal. 10: 79. PMID 32759935 DOI: 10.1038/S41408-020-00346-7 |
0.354 |
|
| 2020 |
Bernard E, Nannya Y, Hasserjian RP, Devlin SM, Tuechler H, Medina-Martinez JS, Yoshizato T, Shiozawa Y, Saiki R, Malcovati L, Levine MF, Arango JE, Zhou Y, Solé F, Cargo CA, et al. Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes. Nature Medicine. PMID 32747829 DOI: 10.1038/S41591-020-1008-Z |
0.355 |
|
| 2020 |
Devlin SM, Gönen M, Heller G. Measuring the temporal prognostic utility of a baseline risk score. Lifetime Data Analysis. PMID 32710191 DOI: 10.1007/S10985-020-09503-3 |
0.302 |
|
| 2020 |
Wudhikarn K, Pennisi M, Garcia-Recio M, Flynn JR, Afuye A, Silverberg ML, Maloy MA, Devlin SM, Batlevi CL, Shah GL, Scordo M, Palomba ML, Dahi PB, Sauter CS, Santomasso BD, et al. DLBCL patients treated with CD19 CAR T cells experience a high burden of organ toxicities but low nonrelapse mortality. Blood Advances. 4: 3024-3033. PMID 32614964 DOI: 10.1182/Bloodadvances.2020001972 |
0.4 |
|
| 2020 |
Politikos I, Devlin SM, Arcila ME, Barone JC, Maloy MA, Naputo KA, Ruiz JD, Mazis CM, Scaradavou A, Avecilla ST, Dahi PB, Giralt SA, Hsu KC, Jakubowski AA, Papadopoulos EB, et al. Engraftment kinetics after transplantation of double unit cord blood grafts combined with haplo-identical CD34+ cells without antithymocyte globulin. Leukemia. PMID 32555371 DOI: 10.1038/S41375-020-0922-X |
0.458 |
|
| 2020 |
Root JC, Campbell C, Rocha-Cadman X, Kasven-Gonzalez N, Maloy M, Flynn J, Devlin SM, Jakubowski AA. Pre-transplant cognitive dysfunction in advanced-age hematologic cancers: predictors and associated outcomes. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. PMID 32447045 DOI: 10.1016/J.Bbmt.2020.05.010 |
0.406 |
|
| 2020 |
Bal S, Landau HJ, Shah GL, Scordo M, Dahi P, Lahoud OB, Hassoun H, Hultcrantz M, Korde N, Lendvai N, Lesokhin AM, Mailankody S, Shah UA, Smith E, Devlin SM, et al. Stem Cell Mobilization and Autograft Minimal Residual Disease Negativity 1 with Novel Induction Regimens in Multiple Myeloma. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. PMID 32442725 DOI: 10.1016/J.Bbmt.2020.04.011 |
0.458 |
|
| 2020 |
Markey KA, Schluter J, Gomes AL, Littmann E, Pickard A, Taylor BP, Giardina PA, Weber D, Dai A, Docampo M, Armijo GK, Slingerland A, Slingerland J, Nichols KB, Brereton DG, ... ... Devlin SM, et al. Microbe-derived short chain fatty acids butyrate and propionate are associated with protection from chronic GVHD. Blood. PMID 32430495 DOI: 10.1182/Blood.2019003369 |
0.421 |
|
| 2020 |
Lin RJ, Ho C, Devlin SM, Ruiz JD, Maloy MA, Shah GL, Perales MA, Dahi PB, Giralt SA, Scordo M, Schöder H, Hamlin PA, Sigler AM, Dogan A, Sauter CS. Impact of allogeneic hematopoietic cell transplantation on immune evasive mechanisms in relapsed refractory large B-cell lymphoma. Bone Marrow Transplantation. PMID 32404978 DOI: 10.1038/S41409-020-0942-1 |
0.425 |
|
| 2020 |
Lin RJ, Michaud L, Lobaugh SM, Nakajima R, Mauguen A, Elko TA, Ruiz JD, Maloy MA, Sauter CS, Dahi PB, Perales MA, Shah GL, Castillo Flores N, Sanchez-Escamilla M, Tomas AA, ... ... Devlin SM, et al. The geriatric syndrome of sarcopenia impacts allogeneic hematopoietic cell transplantation outcomes in older lymphoma patients. Leukemia & Lymphoma. 1-9. PMID 32228298 DOI: 10.1080/10428194.2020.1742909 |
0.474 |
|
| 2020 |
Lin RJ, Cohen AG, Stabler SM, Devlin SM, Elko TA, Maloy MA, Korc-Grodzicki B, Alexander K, Kramer D, Sanchez-Escamilla M, Castillo Flores N, Barker JN, Cho C, Dahi PB, Gyurkocza B, et al. Characteristics and Impact of Post-Transplant Interdisciplinary Palliative Care Consultation in Older Allogeneic Hematopoietic Cell Transplant Recipients. Journal of Palliative Medicine. PMID 32216649 DOI: 10.1089/Jpm.2019.0611 |
0.476 |
|
| 2020 |
Peled JU, Gomes ALC, Devlin SM, Littmann ER, Taur Y, Sung AD, Weber D, Hashimoto D, Slingerland AE, Slingerland JB, Maloy M, Clurman AG, Stein-Thoeringer CK, Markey KA, Docampo MD, et al. Microbiota as Predictor of Mortality in Allogeneic Hematopoietic-Cell Transplantation. The New England Journal of Medicine. 382: 822-834. PMID 32101664 DOI: 10.1056/Nejmoa1900623 |
0.413 |
|
| 2020 |
Pennisi M, Jain T, Santomasso BD, Mead E, Wudhikarn K, Silverberg ML, Batlevi Y, Shouval R, Devlin SM, Batlevi C, Brentjens RJ, Dahi PB, Diamonte C, Giralt S, Halton EF, et al. Comparing CAR T-cell toxicity grading systems: application of the ASTCT grading system and implications for management. Blood Advances. 4: 676-686. PMID 32084260 DOI: 10.1182/Bloodadvances.2019000952 |
0.383 |
|
| 2020 |
Lin RJ, Lobaugh SM, Pennisi M, Chan HT, Batlevi Y, Ruiz JD, Elko TA, Maloy MA, Batlevi CL, Dahi PB, Giralt SA, Hamlin PA, Mead E, Noy A, Palomba ML, ... ... Devlin SM, et al. Impact and safety of chimeric antigen receptor T cell therapy in older, vulnerable patients with relapsed/refractory large b-cell lymphoma. Haematologica. PMID 32079691 DOI: 10.3324/Haematol.2019.243246 |
0.346 |
|
| 2020 |
Hassoun H, Bayer R, Devlin S, Gentile T, Becker M, O'Dweyer K, Lesser M, Landau H, Chung D, Giralt S. A phase II clinical trial of lenalidomide intensification in patients with serologic/asymptomatic progression of multiple myeloma while on lenalidomide maintenance: a tri-state transplant consortium study. Leukemia & Lymphoma. 1-3. PMID 31957517 DOI: 10.1080/10428194.2019.1672058 |
0.387 |
|
| 2020 |
Maples KT, Maloy M, Devlin S, Lin A, DeRespiris L, Griffin M, Lau C, Proli AJ, Papanicolaou GA, Seo SK, Barker JN, Perales MA, Giralt SA, Bhatt V. Lack of a significant pharmacokinetic interaction between letermovir and calcineurin inhibitors in allogeneic HCT recipients. Bone Marrow Transplantation. PMID 31937928 DOI: 10.1038/S41409-020-0785-9 |
0.326 |
|
| 2020 |
Gutgarts V, Sathick IJ, Zheng J, Politikos I, Devlin SM, Maloy MA, Giralt SA, Scordo M, Bhatt V, Glezerman I, Muthukumar T, Jaimes EA, Barker JN. Incidence and Risk Factors for Acute and Chronic Kidney Injury After Adult Cord Blood Transplantation. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. PMID 31911259 DOI: 10.1016/J.Bbmt.2019.12.768 |
0.471 |
|
| 2020 |
Rodriguez N, Lee J, Flynn L, Murray F, Devlin S, Soto Izquierdo C, Cho C, Dahi PB, Giralt SA, Sauter CS, Perales M, Ponce DM. Secondary Graft-Versus-Host Disease (GVHD) Prophylaxis with Oral Proteasome Inhibitor Ixazomib Is Associated with Low Incidence of Recurrent, Late Acute and Chronic GVHD and Facilitated Calcineurin Inhibitor Taper within the First Year Post Allogeneic Stem Cell Transplantation Blood. 136: 41-42. DOI: 10.1182/blood-2020-139666 |
0.374 |
|
| 2020 |
Nawas MT, Sanchez-Escamilla M, Devlin SM, Maloy MA, Perales M, Giralt SA, Scordo M. Prediction of Non-Relapse Mortality with Dynamic Easix Scores after Allogeneic Hematopoietic Cell Transplantation Biology of Blood and Marrow Transplantation. 26. DOI: 10.1016/J.Bbmt.2019.12.755 |
0.44 |
|
| 2020 |
Peterson KT, Lin A, Ruiz JD, Zheng J, Devlin SM, Shah GL, Scordo M, Sauter CS, Perales M, Giralt SA, Buie LW, Dahi PB. Comparison of Conditioning Regimens for Allogeneic Hematopoietic Cell Transplantation in Non-Hodgkin Lymphoma Biology of Blood and Marrow Transplantation. 26: 161-162. DOI: 10.1016/J.Bbmt.2019.12.716 |
0.483 |
|
| 2020 |
Scordo M, Cho C, Devlin SM, Maloy MA, Ruiz JD, Bhatt V, Smith M, Shah GL, O'Reilly RJ, Papadopoulos EB, Jakubowski AA, Tamari R, Perales M, Giralt SA, Boelens J. Population Pharmacokinetic Model Demonstrates Poor Outcomes with ATG Overexposure in Adults Undergoing Ex Vivo CD34-Selected Allogeneic Hematopoietic Cell Biology of Blood and Marrow Transplantation. 26: S157. DOI: 10.1016/J.Bbmt.2019.12.710 |
0.417 |
|
| 2020 |
Shah GL, Lin A, Kamrowski A, Carino CA, Schofield R, Devlin SM, Bhatt V, Proli AJ, Chung DJ, Dahi PB, Lahoud OB, Scordo M, Carlow D, Giralt SA, Landau HJ. Successful Personalization of Propylene Glycol Free Melphalan (PGF-MEL) for Multiple Myeloma (MM) and AL Amyloidosis (AL) Patients Undergoing Autologous Hematopoietic Stem Cell Transplant (AHCT) Using Pharmacokinetic (PK)-Directed Dosing Biology of Blood and Marrow Transplantation. 26. DOI: 10.1016/J.Bbmt.2019.12.707 |
0.4 |
|
| 2020 |
Pennisi M, Cho C, Devlin SM, Ruiz JD, Maloy MA, Tomas AA, Castillo N, Lin RJ, Politikos I, Sanchez-Escamilla M, Scordo M, Shah GL, Barker JN, Castro-Malaspina H, Gyurkocza B, et al. Don't Let the HCT-CI Fool You: Similar Outcomes with Myeloablative CD34+ Selected Allo-HCT Compared to Unmodified RIC Allo-HCT in Patients with AML or MDS and High Comorbidity Scores. Biology of Blood and Marrow Transplantation. 26. DOI: 10.1016/J.Bbmt.2019.12.704 |
0.428 |
|
| 2020 |
Shouval R, Fein JA, Devlin SM, Maloy MA, Flores NC, Lin RJ, Politikos I, Sanchez M, Scordo M, Shah GL, Barker JN, Giralt SA, Gyurkocza B, Jakubowski AA, Papadopoulos EB, et al. The Impact of Individual Co-Morbidities in Myeloablative Ex Vivo CD34+ Selected Allogeneic Hematopoietic Cell Transplantation Biology of Blood and Marrow Transplantation. 26: S141. DOI: 10.1016/J.Bbmt.2019.12.669 |
0.473 |
|
| 2020 |
Shaffer BC, Park S, Luduec JL, Devlin SM, Jakubowski AA, Gyurkocza B, Papadopoulos EB, Tamari R, Giralt SA, Hsu KC. Prospective Identification of Unrelated Donors with Low Inhibitory Donor KIR3DL1 – Recipient HLA-B Interaction Decreases Relapse and Improves Survival after Allogeneic Hematopoietic Cell Transplantation for Myeloid Neoplasia Biology of Blood and Marrow Transplantation. 26. DOI: 10.1016/J.Bbmt.2019.12.640 |
0.492 |
|
| 2020 |
Brambilla CZ, Ruiz JD, Lobaugh SM, Dahi PB, Young JW, Gyurkocza B, Shaffer BC, Ponce DM, Tamari R, Escamilla MS, Flores NC, Politikos I, Scordo M, Shah GL, Cho C, ... ... Devlin SM, et al. Long-Term Survival in Patients with AML or MDS Relapsed after Allogeneic Hematopoietic Cell Transplantation: Importance of Second Cell Therapy Biology of Blood and Marrow Transplantation. 26: S97-S98. DOI: 10.1016/J.Bbmt.2019.12.598 |
0.533 |
|
| 2020 |
Davis E, Devlin SM, Cooper C, Nhaissi M, Wells DS, Giralt SA, Papadopoulos EB, Politikos I, Barker JN. Comparison of Search Prognosis Algorithms Demonstrates the Value of HapLogicTM-Based Assessment in Predicting the Likelihood of Identifying 8/8 HLA-Allele Matched Unrelated Donors (URD) & Receiving an 8/8 URD Transplant Biology of Blood and Marrow Transplantation. 26. DOI: 10.1016/J.Bbmt.2019.12.572 |
0.433 |
|
| 2020 |
Wudhikarn K, Pennisi M, Recio MG, Flynn J, Maloy MA, Devlin SM, Batlevi CW, Shah GL, Scordo M, Palomba ML, Dahi PB, Sauter CS, Perales M. Burden and Impact of Toxicities on Outcomes for Aggressive B Cell Non-Hodgkin Lymphoma Patients after CD19-Directed Chimeric Antigen Receptor T Cell: Real-World Experience Biology of Blood and Marrow Transplantation. 26: 263-264. DOI: 10.1016/J.Bbmt.2019.12.428 |
0.416 |
|
| 2020 |
Jain T, Knezevic A, Pennisi M, Ruiz JD, Devlin SM, Halton E, Diamonte C, Scordo M, Sauter CS, Mead E, Santomasso B, Palomba ML, Shah GL, Batlevi CW, Maloy MA, et al. Hematopoietic Recovery Following Chimeric Antigen Receptor T Cell (CAR T) Therapy in Hematological Malignancies Biology of Blood and Marrow Transplantation. 26: S63-S64. DOI: 10.1016/J.Bbmt.2019.12.231 |
0.441 |
|
| 2020 |
Pennisi M, Jain T, Mead E, Santomasso B, Silverberg ML, Batlevi Y, Shouval R, Devlin SM, Batlevi CW, Brentjens R, Dahi PB, Diamonte C, Giralt SA, Halton E, Maloy MA, et al. Comparing Car T Cells Toxicities Grading Systems: Application of Astct Grading System and Implications for Management Biology of Blood and Marrow Transplantation. 26. DOI: 10.1016/J.Bbmt.2019.12.107 |
0.321 |
|
| 2020 |
Politikos I, Maloy MA, Devlin SM, Naputo K, Bhatt V, Skinner K, Cho C, Dahi PB, Giralt SA, Gyurkocza B, Hanash AM, Jakubowski AA, Papadopoulos EB, Perales M, Peled JU, et al. Addition of Tocilizumab to Cyclosporine-a/ Mycophenolate Mofetil (CSA/ MMF) Graft-Vs-Host Disease (GVHD) Prophylaxis Significantly Abrogates Pre-Engraftment Syndrome (PES) & Severe Acute Gvhd after Adult Double Unit Cord Blood Transplantation (dCBT) Biology of Blood and Marrow Transplantation. 26. DOI: 10.1016/J.Bbmt.2019.12.100 |
0.496 |
|
| 2020 |
Purvey S, Seier K, Devlin SM, Ruiz JD, Maloy MA, Shah GL, Hassoun H, Giralt SA, Landau HJ. Difference in Involved and Uninvolved Free Light Chain (dFLC) of Less Than 1mg/Dl Early Post Risk Adapted Melphalan and Autologous Stem Cell Transplantation (RA-ASCT) Predicts Renal Response (RR) at 1 Year in Light Chain (AL) Amyloidosis Biology of Blood and Marrow Transplantation. 26. DOI: 10.1016/J.Bbmt.2019.12.087 |
0.37 |
|
| 2020 |
Menghrajani K, Zhang M, Bo-Subait K, Wang H, Devlin SM, Madero-Marroquin R, Arteaga AG, Sandmaier BM, Litzow MR, Kebriaei P, Weisdorf DJ, Zhang Y, Tallman M, Saber W. MLL-Rearranged AML Is Associated with Poor Outcomes As Compared to Patients with Intermediate- and Adverse-Risk Disease: A CIBMTR Study of 3779 Adult Patients Biology of Blood and Marrow Transplantation. 26. DOI: 10.1016/J.Bbmt.2019.12.074 |
0.433 |
|
| 2019 |
Takashima S, Martin ML, Jansen SA, Fu Y, Bos J, Chandra D, O'Connor MH, Mertelsmann AM, Vinci P, Kuttiyara J, Devlin SM, Middendorp S, Calafiore M, Egorova A, Kleppe M, et al. T cell-derived interferon-γ programs stem cell death in immune-mediated intestinal damage. Science Immunology. 4. PMID 31811055 DOI: 10.1126/Sciimmunol.Aay8556 |
0.357 |
|
| 2019 |
Stein-Thoeringer CK, Nichols KB, Lazrak A, Docampo MD, Slingerland AE, Slingerland JB, Clurman AG, Armijo G, Gomes ALC, Shono Y, Staffas A, Burgos da Silva M, Devlin SM, Markey KA, Bajic D, et al. Lactose drives expansion to promote graft-versus-host disease. Science (New York, N.Y.). 366: 1143-1149. PMID 31780560 DOI: 10.1126/Science.Aax3760 |
0.412 |
|
| 2019 |
Barker JN, Mazis C, Devlin SM, Davis E, Maloy MA, Naputo K, Nhaissi M, Wells D, Scaradavou A, Politikos I. Evaluation of Cord Blood Total Nucleated and CD34+ Cell Content, Cell Dose and 8-allele HLA-Match by Patient Ancestry. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. PMID 31756534 DOI: 10.1016/J.Bbmt.2019.11.017 |
0.427 |
|
| 2019 |
Lin RJ, Sanchez M, Abbi K, Devlin SM, Jakubowski AA, Papadopoulos EB, Barker JN, Tamari R, Young JW, Gyurkocza B, Ponce DM, Dahi PB, Maloy MA, Giralt SA, Perales MA, et al. Favorable long-term outcomes of hematopoietic stem cell transplantation for CMML with myeloablative conditioning, anti-thymocyte globulin, and CD34 selected graft. Bone Marrow Transplantation. PMID 31645667 DOI: 10.1038/S41409-019-0723-X |
0.425 |
|
| 2019 |
Lin RJ, Elko TA, Devlin SM, Shahrokni A, Jakubowski AA, Dahi PB, Perales MA, Tamari R, Shaffer BC, Sauter CS, Papadopoulos EB, Gyurkocza B, Korc-Grodzicki B, Barker JN, Maloy MA, et al. Impact of geriatric vulnerabilities on allogeneic hematopoietic cell transplantation outcomes in older patients with hematologic malignancies. Bone Marrow Transplantation. PMID 31471572 DOI: 10.1038/S41409-019-0654-6 |
0.504 |
|
| 2019 |
Landau H, Lahoud O, Devlin S, Lendvai N, Chung DJ, Dogan A, Landgren CO, Giralt S, Hassoun H. Pilot Study of Bortezomib and Dexamethasone Pre- and Post-Risk-Adapted Autologous Stem Cell Transplantation in AL Amyloidosis. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. PMID 31446197 DOI: 10.1016/J.Bbmt.2019.08.016 |
0.451 |
|
| 2019 |
Stanchina M, Pastore A, Devlin S, Famulare C, Stein E, Taylor J. CD33 splice site genotype was not associated with outcomes of patients receiving the anti-CD33 drug conjugate SGN-CD33A. Journal of Hematology & Oncology. 12: 85. PMID 31439003 DOI: 10.1186/S13045-019-0771-0 |
0.312 |
|
| 2019 |
Martin GH, Roy N, Chakraborty S, Desrichard A, Chung SS, Woolthuis CM, Hu W, Berezniuk I, Garrett-Bakelman FE, Hamann J, Devlin SM, Chan TA, Park CY. CD97 is a critical regulator of acute myeloid leukemia stem cell function. The Journal of Experimental Medicine. PMID 31371381 DOI: 10.1084/Jem.20190598 |
0.337 |
|
| 2019 |
Klager S, Lacouture ME, Hannum M, Devlin SM, Maloy M, Pulitzer M, Jakubowski AA, Markova A. Drugs as a Frequent Cause of Acute Rash in Patients After CD34-selected Peripheral Blood Stem Cell Transplantation. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. PMID 31306779 DOI: 10.1016/J.Bbmt.2019.07.009 |
0.445 |
|
| 2019 |
Pianko MJ, Devlin SM, Littmann ER, Chansakul A, Mastey D, Salcedo M, Fontana E, Ling L, Tavitian E, Slingerland JB, Slingerland AE, Clurman A, Gomes ALC, Taur Y, Pamer EG, et al. Minimal residual disease negativity in multiple myeloma is associated with intestinal microbiota composition. Blood Advances. 3: 2040-2044. PMID 31289031 DOI: 10.1182/Bloodadvances.2019032276 |
0.412 |
|
| 2019 |
Lin RJ, Dahi PB, Shahrokni A, Sarraf S, Korc-Grodzicki B, Devlin SM, Maloy MA, Shah GL, Jakubowski AA, Giralt SA. Feasibility of a patient-reported, electronic geriatric assessment tool in hematopoietic cell transplantation - a single institution pilot study. Leukemia & Lymphoma. 1-4. PMID 31226901 DOI: 10.1080/10428194.2019.1630621 |
0.43 |
|
| 2019 |
Epstein-Peterson ZD, Devlin SM, Stein EM, Klimek VM, Saltz LB, Tallman MS. Molecular and cytogenetic characteristics of myeloid malignancies following luminal gastrointestinal cancer. Leukemia Research. 82: 19-23. PMID 31151028 DOI: 10.1016/J.Leukres.2019.05.010 |
0.31 |
|
| 2019 |
Geyer MB, Rivière I, Sénéchal B, Wang X, Wang Y, Purdon TJ, Hsu M, Devlin SM, Palomba ML, Halton E, Bernal Y, Sadelain M, Park JH, Brentjens RJ. Safety and tolerability of conditioning chemotherapy followed by CD19-targeted CAR T cells for relapsed/refractory CLL. Jci Insight. 5. PMID 30938714 DOI: 10.1172/Jci.Insight.122627 |
0.358 |
|
| 2019 |
Barker JN, Boughan K, Dahi PB, Devlin SM, Maloy MA, Naputo K, Mazis CM, Davis E, Nhaissi M, Wells D, Cooper C, Ponce DM, Kernan N, Scaradavou A, Giralt SA, et al. Racial disparities in access to HLA-matched unrelated donor transplants: a prospective 1312-patient analysis. Blood Advances. 3: 939-944. PMID 30917950 DOI: 10.1182/Bloodadvances.2018028662 |
0.464 |
|
| 2019 |
Mailankody S, Salcedo M, Tavitian E, Korde N, Lendvai N, Hassoun H, Lesokhin AM, Lahoud OB, Smith EL, Hultcrantz M, Devlin SM, Landgren O. Ixazomib and dexamethasone in high risk smoldering multiple myeloma: A clinical and correlative pilot study. Journal of Clinical Oncology. 37: 8051-8051. DOI: 10.1200/Jco.2019.37.15_Suppl.8051 |
0.323 |
|
| 2019 |
Lin RJ, Elko TA, Devlin SM, Flynn J, Jakubowski AA, Shahrokni A, Dahi P, Perales M, Sanchez-Escamilla M, Tamari R, Shaffer BC, Sauter CS, Papadopoulos EB, Castro-Malaspina H, Gyurkocza B, et al. Impact of geriatric vulnerability on outcomes of older patients in allogeneic hematopoietic cell transplantation. Journal of Clinical Oncology. 37: 7017-7017. DOI: 10.1200/Jco.2019.37.15_Suppl.7017 |
0.506 |
|
| 2019 |
Peled JU, Gomes ALC, Devlin SM, Littmann ER, Taur Y, Sung AD, Weber D, Hashimoto D, Wright RJ, Amoretti L, Fontana E, Perales M, Giralt S, Jenq RR, Teshima T, et al. Inferior survival after microbiota injury: A multicenter allo-HCT study. Journal of Clinical Oncology. 37: 7015-7015. DOI: 10.1200/Jco.2019.37.15_Suppl.7015 |
0.422 |
|
| 2019 |
Bernard E, Nannya Y, Yoshizato T, Hasserjian RP, Saiki R, Shiozawa Y, Devlin SM, Tuechler H, Sarian A, Malcovati L, Sole F, Haase D, Creignou M, Levine M, Germing U, et al. TP53 State Dictates Genome Stability, Clinical Presentation and Outcomes in Myelodysplastic Syndromes Blood. 134: 675-675. DOI: 10.1182/Blood-2019-129392 |
0.32 |
|
| 2019 |
Purvey S, Seier K, Devlin SM, Ruiz JD, Maloy MA, Shah GL, Hassoun H, Giralt SA, Landau HJ. Difference in Involved and Uninvolved Free Light Chain (dFLC) of Less Than 1mg/DL Early Post Risk Adapted Melphalan and Autologous Stem Cell Transplantation (RA-ASCT) Predicts Renal Response at 1 Year in Light Chain (AL) Amyloidosis Blood. 134: 4577-4577. DOI: 10.1182/Blood-2019-129195 |
0.353 |
|
| 2019 |
Rampal RK, Verstovsek S, Devlin SM, King AC, Stein EM, Pemmaraju N, Mauro MJ, Kadia TM, Montalban-Bravo G, Alvarez K, Ard N, Goodman T, Taylor B, Bose P. Safety and Efficacy of Combined Ruxolitinib and Thalidomide in Patients with Myelofibrosis: A Phase II Study Blood. 134: 4163-4163. DOI: 10.1182/Blood-2019-127661 |
0.322 |
|
| 2019 |
Jain T, Knezevic A, Pennisi M, Ruiz JD, Devlin SM, Maloy MA, Halton E, Diamonte C, Scordo M, Sauter CS, Mead E, Santomasso B, Palomba ML, Shah GL, Batlevi CL, et al. Hematological Count Recovery in Patients Undergoing Treatment with Chimeric Antigen Receptor T Cells (CAR T) Blood. 134: 4455-4455. DOI: 10.1182/Blood-2019-127480 |
0.304 |
|
| 2019 |
Pennisi M, Sanchez-Escamilla M, Flynn J, Maloy MA, Silverberg ML, Batlevi Y, Shouval R, Batlevi CL, Brentjens RJ, Devlin SM, Dahi PB, Diamonte C, Giralt SA, Halton E, Jain T, et al. Easix and Modified-Easix Are Early Predictors of Severe Cytokine Release Syndrome and Neurotoxicity in Patients Treated with Chimeric Antigen Receptor T Cells Blood. 134: 1947-1947. DOI: 10.1182/Blood-2019-126208 |
0.311 |
|
| 2019 |
Landgren O, Mastey D, Lesokhin AM, Smith EL, Shah UA, Mailankody S, Hultcrantz M, Hassoun H, Lu SX, Salcedo M, Diab V, Werner K, Rispoli J, Sams A, Verducci D, ... ... Devlin SM, et al. Long-Term Sustained Minimal Residual Disease (MRD) Negativity in Multiple Myeloma Patients Treated with Lenalidomide Maintenance Therapy: A Clinical and Correlative Phase 2 Study Blood. 134: 3127-3127. DOI: 10.1182/Blood-2019-125842 |
0.309 |
|
| 2019 |
Nawas MT, Sanchez-Escamilla M, Devlin SM, Maloy MA, Giralt SA, Perales M, Scordo M. Dynamic Easix Scores Closely Predict Non-Relapse Mortality after Allogeneic Hematopoietic Cell Transplantation Blood. 134: 1971-1971. DOI: 10.1182/Blood-2019-125834 |
0.413 |
|
| 2019 |
Lin RJ, Lobaugh SM, Pennisi M, Chan JT, Batlevi Y, Ruiz JD, Elko TA, Maloy MA, Batlevi CL, Dahi PB, Giralt SA, Mead E, Noy A, Palomba ML, Santomasso B, ... ... Devlin SM, et al. Impact and Safety of Chimeric Antigen Receptor T Cell Therapy in Vulnerable Older Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Blood. 134: 1603-1603. DOI: 10.1182/Blood-2019-125162 |
0.39 |
|
| 2019 |
Lin RJ, Michaud L, Lobaugh SM, Nakajima R, Elko TA, Ruiz JD, Sauter CS, Dahi PB, Maloy MA, Perales M, Kim SJ, Korc-Grodzicki B, Devlin SM, Scordo M, Schoder H, et al. The Geriatric Syndrome of Sarcopenia Impacts Allogeneic Hematopoietic Cell Transplantation Outcomes in Combination with Multi-Morbidity and Functional Impairment Blood. 134: 4508-4508. DOI: 10.1182/Blood-2019-125141 |
0.457 |
|
| 2019 |
Piedra KM, Hassoun H, Buie LW, Devlin SM, Flynn J, Hultcrantz M, Lesokhin AM, Lu SX, Mailankody S, Shah UA, Smith EL, Landgren O, Korde N, Peterson TJ. VTE Rates and Safety Analysis of Newly Diagnosed Multiple Myeloma Patients Receiving Carfilzomib-Lenalidomide-Dexamethasone (KRD) with or without Rivaroxaban Prophylaxis Blood. 134: 1835-1835. DOI: 10.1182/Blood-2019-124403 |
0.327 |
|
| 2019 |
Alarcon A, Devlin S, Maloy M, Ruiz J, Escamilla MS, Tamari R, Shaffer B, Castro-Malaspina H, Giralt S, Perales M. PF546 THE SFGM-TC MDS SCORE AT DAY 180 IS ASSOCIATED WITH POST-TRANSPLANT OUTCOMES IN PATIENTS WITH MYELODYSPLASTIC SYNDROME WHO UNDERWENT CD34+ SELECTED ALLOGENEIC STEM CELL TRANSPLANT Hemasphere. 3: 225. DOI: 10.1097/01.HS9.0000560280.92775.52 |
0.396 |
|
| 2019 |
Park C, Martin G, Roy N, Chakraborty S, Desrichard A, chung S, Woolthuis C, Hu W, berezniuk I, Garrett-Bakelman F, Hamann J, Devlin s, chan T. 1018 - CD97 IS A CRITICAL REGULATOR OF ACUTE MYELOID LEUKEMIA STEM CELL FUNCTION Experimental Hematology. 76: S31. DOI: 10.1016/J.Exphem.2019.06.256 |
0.349 |
|
| 2019 |
Shah G, Lin A, Grumley A, Kamrowski A, Schofield R, Devlin S, Bhatt V, Proli A, Chung D, Dahi P, Lahoud O, Scordo M, Carlow D, Giralt S, Landau H. Successful Pharmacokinetic (PK)-Directed Dosing of Evomela® (propylene glycol free melphalan, PGF-MEL) for Multiple Myeloma (MM) and AL Amyloidosis (AL) Patients Undergoing Autologous Hematopoietic Stem Cell Transplant (AHCT) Clinical Lymphoma, Myeloma & Leukemia. 19. DOI: 10.1016/J.Clml.2019.09.492 |
0.422 |
|
| 2019 |
Shah G, Holder J, Cho S, Murata K, Devlin S, Hoover E, Chung D, Dahi P, Lahoud O, Scordo M, Landau H, Giralt S. Interleukin-6 (IL-6) Blockade with Siltuximab Peri-Autologous Hematopoietic Stem Cell Transplantation (AHCT) May Reduce Symptom Burden by Altering the Cytokine Milieu in Older Patients with Multiple Myeloma (MM) Clinical Lymphoma, Myeloma & Leukemia. 19. DOI: 10.1016/J.Clml.2019.09.491 |
0.398 |
|
| 2019 |
Preston EV, Palazzo M, Seier K, Maloy MA, Devlin SM, Giralt SA, Scordo M, Dahi PB, Matasar MJ, Moskowitz CH, Sauter CS, Shah GL, Perales M. Efficacy of Revaccination after Autologous Hematopoietic Stem Cell Transplantation in Lymphoma Patients with or without Rituximab Exposure Biology of Blood and Marrow Transplantation. 25. DOI: 10.1016/J.Bbmt.2018.12.531 |
0.374 |
|
| 2019 |
Dahi PB, Lin RJ, Shahrokni A, Maloy MA, Devlin SM, Petrlik E, Ayala J, Brown S, Giralt SA, Jakubowski AA. Feasibility and Clinical Utility of Electronic Geriatric Assessment (eGA) in Older Patients Undergoing Hematopoietic Cell Transplantation Biology of Blood and Marrow Transplantation. 25. DOI: 10.1016/J.Bbmt.2018.12.432 |
0.479 |
|
| 2019 |
Gutgarts V, Zheng J, Politikos I, Devlin SM, Maloy MA, Giralt SA, Scordo M, Bhatt V, Glezerman I, Jaimes EA, Thangamani M, Sathick IJ, Barker JN. Adult Cord Blood Transplantation (CBT) Recipients Have a High Incidence of Early Acute Kidney Injury (AKI) and AKI Increases Long-Term Chronic Kidney Disease (CKD) Risk Biology of Blood and Marrow Transplantation. 25. DOI: 10.1016/J.Bbmt.2018.12.415 |
0.416 |
|
| 2019 |
Lin RJ, Elko TA, Devlin SM, Perales M, Papadopoulos EB, Castro-Malaspina H, Gyurkocza B, Shaffer BC, Tamari R, Tallman M, Stein E, Goldberg AD, Maloy MA, Giralt SA, Jakubowski AA. Impact of Pre-Transplant Measurable Residual Disease on Relapse Incidence and Progression-Free Survival in Older AML/MDS Patients Following Allogeneic Hematopoietic Cell Transplantation Biology of Blood and Marrow Transplantation. 25. DOI: 10.1016/J.Bbmt.2018.12.391 |
0.508 |
|
| 2019 |
Bhatt V, Devlin SM, Maloy MA, Mazis C, Naputo K, Giralt SA, Politikos I, Barker JN. Pre-Engraftment Syndrome (PES) Is Frequent in Double Unit Cord Blood Transplantation (dCBT) Recipients and Is Potentiated By the Addition of Haplo-Identical CD34+ Cells Biology of Blood and Marrow Transplantation. 25. DOI: 10.1016/J.Bbmt.2018.12.358 |
0.455 |
|
| 2019 |
Mazis C, Politikos I, Devlin SM, Maloy MA, Naputo K, Davis E, Cooper C, Nhaissi M, Suri B, Wells DS, Giralt SA, Shah GL, Scaradavou A, Barker JN. Evaluation of Cord Blood (CB) TNC & CD34+ Cell Content, Cell Dose & Donor-Recipient 8-Allele HLA-Match By Patient Ancestry: An Analysis of 544 Units in a Racially & Ethnically Diverse Patient Population Biology of Blood and Marrow Transplantation. 25. DOI: 10.1016/J.Bbmt.2018.12.286 |
0.391 |
|
| 2019 |
Politikos I, Devlin SM, Maloy MA, Mazis C, Naputo K, Afuye A, Scaradavou A, O'Reilly RJ, Avecilla ST, Castro-Malaspina H, Cho C, Dahi PB, Giralt SA, Gyurkocza B, Jakubowski AA, et al. Engrafting Unit-Recipient HLA-Allele Mismatch Is Not Associated with an Increased Risk of Transplant-Related Mortality (TRM) or Inferior Progression-Free Survival (PFS) after Double Unit Cord Blood (CB) Transplantation (dCBT) in Adults with Hematologic Malignancies Biology of Blood and Marrow Transplantation. 25: S208-S209. DOI: 10.1016/J.Bbmt.2018.12.285 |
0.464 |
|
| 2019 |
Politikos I, Devlin SM, Mazis C, Maloy MA, Naputo K, Afuye A, Avecilla ST, Castro-Malaspina H, Dahi PB, Giralt SA, Sauter CS, Scordo M, Shaffer BC, Shah GL, Tamari R, et al. Double-Unit Cord Blood (CB) Transplantation (dCBT) Supplemented with Haplo-Identical CD34+ Cells May be Associated with Enhanced Neutrophil Recovery but Successful Myeloid Bridging Is Strongly Influenced By Haplo CD34+ Cell Dose and Haplo-Winning CB Unit HLA-Match Biology of Blood and Marrow Transplantation. 25: S207-S208. DOI: 10.1016/J.Bbmt.2018.12.284 |
0.459 |
|
| 2019 |
Markey KA, Gomes A, Littmann E, Devlin SM, Slingerland AE, Moore G, Fatmi S, Slingerland J, Clurman A, Maloy MA, Pamer EG, Taur Y, Giralt SA, Perales M, Ponce DM, et al. Pre-Transplant and Peri-d100 Gastrointestinal Dysbiosis Is Associated with the Subsequent Development of Chronic Graft-Versus-Host Disease Biology of Blood and Marrow Transplantation. 25: S254-S255. DOI: 10.1016/J.Bbmt.2018.12.257 |
0.444 |
|
| 2019 |
Fonseca M, Jakubowski AA, Devlin SM, Young JW, Fatmi S, Maloy MA, Giralt SA, Ponce DM, Markova A. HLA-a*0101 Allele Is Associated with Increased Risk of Cutaneous Acute Graft-Versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation Biology of Blood and Marrow Transplantation. 25. DOI: 10.1016/J.Bbmt.2018.12.244 |
0.483 |
|
| 2019 |
Politikos I, Maloy MA, Devlin SM, Naputo K, Bhatt V, Cho C, Giralt SA, Gyurkocza B, Hanash AM, Papadopoulos EB, Peled JU, Tamari R, Ponce DM, Barker JN. Addition of Tocilizumab to Cyclosporine/ MMF for Acute Graft-Vs-Host Disease (aGVHD) Prophylaxis in Adult Double Unit Cord Blood Transplant (dCBT) Recipients: Promising Preliminary Results of a Phase II Clinical Trial. Biology of Blood and Marrow Transplantation. 25. DOI: 10.1016/J.Bbmt.2018.12.216 |
0.395 |
|
| 2019 |
Lau C, Politikos I, Maloy MA, Naputo K, Afuye A, Devlin SM, Bhatt V, Giralt SA, Jakubowski AA, Papadopoulos EB, Perales M, Shaffer BC, Seo SK, Papanicolaou GA, Barker JN. Letermovir Prophylaxis Demonstrates High Efficacy in Adult Cytomegalovirus (CMV) Seropositive Cord Blood Transplant (CBT) Recipients: A Comparison with Pre-Letermovir Era CBT Controls Biology of Blood and Marrow Transplantation. 25. DOI: 10.1016/J.Bbmt.2018.12.182 |
0.424 |
|
| 2019 |
Politikos I, Cho C, Devlin SM, Maloy MA, Naputo K, O'Reilly RJ, Scaradavou A, Castro-Malaspina H, Dahi PB, Gyurkocza B, Jakubowski AA, Papadopoulos EB, Ponce DM, Sauter CS, Scordo M, et al. Comparison of Double Unit Cord Blood Transplants (dCBT) with 8/8 HLA-Allele Matched Related (MRD) or Unrelated Donor (MUD) T-Cell Depleted (TCD) Transplants in Adults with Myeloid Malignancies: Comparable Progression-Free Survival (PFS) Biology of Blood and Marrow Transplantation. 25: S58-S59. DOI: 10.1016/J.Bbmt.2018.12.137 |
0.489 |
|
| 2019 |
Khan N, Peled JU, Gomes A, Devlin SM, Clavo CR, Clurman A, Slingerland J, Slingerland AE, Maloy MA, Sung AD, Chao NJ, Markey KA, Sauter CS, Landau H, Ponce DM, et al. Microbiota Injury in Auto-HCT Is Frequent, Occurs across Geography, and Is Comparable to That Observed in Allo-HCT Biology of Blood and Marrow Transplantation. 25: S44-S45. DOI: 10.1016/J.Bbmt.2018.12.120 |
0.439 |
|
| 2019 |
Vinci P, Garcia-Martinez E, O'Connor MH, Egorova A, Mertelsmann AM, Nicoletti E, Geary CD, Devlin SM, Brink MRMvd, Jenq RR, Hanash AM. Graft-Versus-Host Disease Leads to Systemic Elimination of Innate Lymphoid Cells and Abolishes Their Development Biology of Blood and Marrow Transplantation. 25. DOI: 10.1016/J.Bbmt.2018.12.098 |
0.413 |
|
| 2019 |
Sauter C, Lin R, Ho C, Devlin S, Maloy M, Perales M, Dahi P, Schoder H, Jakubowski A, Barker J, Papadopoulos E, Giralt S. ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION IMPACTS ON IMMUNE EVASIVE MECHANISMS IN RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA - A SINGLE CENTER EXPERIENCE Hematological Oncology. 37: 438-439. DOI: 10.1002/Hon.113_2631 |
0.406 |
|
| 2018 |
Xiao W, Goldberg AD, Famulare C, Devlin S, Nguyen N, Sim S, Kabel CC, Patel MA, McGovern E, Patel A, Schulman J, Dunbar A, Epstein-Peterson ZD, Menghrajani K, Getta BM, et al. Loss of plasmacytoid dendritic cell differentiation is highly predictive for post-induction measurable residual disease and inferior outcomes in acute myeloid leukemia. Haematologica. PMID 30523054 DOI: 10.3324/Haematol.2018.203018 |
0.411 |
|
| 2018 |
Lin RJ, Elko TA, Perales MA, Alexander K, Jakubowski AA, Devlin SM, Dahi PB, Papadopoulos EB, Klimek VM, Giralt SA, Nelson JE. End-of-life care for older AML patients relapsing after allogeneic stem cell transplant at a dedicated cancer center. Bone Marrow Transplantation. PMID 30135464 DOI: 10.1038/S41409-018-0311-5 |
0.429 |
|
| 2018 |
Geyer MB, Rivière I, Sénéchal B, Wang X, Wang Y, Purdon TJ, Hsu M, Devlin SM, Halton E, Lamanna N, Rademaker J, Sadelain M, Brentjens RJ, Park JH. Autologous CD19-Targeted CAR T Cells in Patients with Residual CLL following Initial Purine Analog-Based Therapy. Molecular Therapy : the Journal of the American Society of Gene Therapy. PMID 29910179 DOI: 10.1016/J.Ymthe.2018.05.018 |
0.395 |
|
| 2018 |
Mantha S, Tallman MS, Devlin SM, Soff GA. Predictive factors of fatal bleeding in acute promyelocytic leukemia. Thrombosis Research. 164: S98-S102. PMID 29703492 DOI: 10.1016/J.Thromres.2018.01.038 |
0.343 |
|
| 2018 |
Rosillo C, Avila AM, Huang YT, Devlin S, Cho C, Montoro J, Maloy MA, Papanicolaou GA, Barba P, Perales MA. Sequential systematic anti-mold prophylaxis with micafungin and voriconazole results in very low incidence of invasive mold infections in patients undergoing allogeneic hematopoietic stem cell transplantation. Transplant Infectious Disease : An Official Journal of the Transplantation Society. e12897. PMID 29668073 DOI: 10.1111/Tid.12897 |
0.481 |
|
| 2018 |
Lin RJ, Shahrokni A, Dahi PB, Jakubowski AA, Devlin SM, Maloy MA, Robinson KS, Perales MA, Shah GL, Korc-Grodzicki B, Giralt SA. Pretransplant comprehensive geriatric assessment in hematopoietic cell transplantation: a single center experience. Bone Marrow Transplantation. PMID 29523890 DOI: 10.1038/S41409-018-0151-3 |
0.423 |
|
| 2018 |
Epstein-Peterson ZD, Devlin SM, Stein EM, Estey E, Tallman MS. Widespread use of measurable residual disease in acute myeloid leukemia practice. Leukemia Research. 67: 92-98. PMID 29482173 DOI: 10.1016/J.Leukres.2018.02.006 |
0.318 |
|
| 2018 |
Burke PW, Aldoss I, Lunning MA, Devlin SM, Tallman MS, Pullarkat V, Mohrbacher AM, Douer D. Pegaspargase-related high-grade hepatotoxicity in a pediatric-inspired adult acute lymphoblastic leukemia regimen does not predict recurrent hepatotoxicity with subsequent doses. Leukemia Research. 66: 49-56. PMID 29407583 DOI: 10.1016/J.Leukres.2017.12.013 |
0.333 |
|
| 2018 |
Sauter CS, Matasar MJ, Schoder H, Devlin SM, Drullinsky P, Gerecitano J, Kumar A, Noy A, Palomba ML, Portlock CS, Straus DJ, Zelenetz AD, McCall SJ, Miller ST, Courtien AI, et al. A Phase I Study of Ibrutinib in Combination with R-ICE in Patients with Relapsed or Primary Refractory DLBCL. Blood. PMID 29386196 DOI: 10.1182/Blood-2017-08-802561 |
0.436 |
|
| 2018 |
Tamari R, Oran B, Hilden P, Maloy M, Kongtim P, Papadopoulos EB, Rondon G, Jakubowski AA, Andersson BS, Devlin SM, Ahmed S, Popat UR, Ponce D, Chen J, Sauter C, et al. Allogeneic Stem Cell Transplantation for Advanced Myelodysplastic Syndrome: Comparison of Outcomes between CD34+ Selected or Unmodified Hematopoietic Stem Cells Transplants. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. PMID 29325829 DOI: 10.1016/J.Bbmt.2018.01.001 |
0.467 |
|
| 2018 |
Getta BM, Devlin S, Park JH, Tallman MS, Berman E. Disease characteristics and clinical outcomes in patients aged less than 40 with chronic lymphocytic leukemia. Leukemia Research. 65: 80-85. PMID 29316456 DOI: 10.1016/J.Leukres.2017.12.008 |
0.389 |
|
| 2018 |
Barba P, Martino R, Zhou Q, Cho C, Castro-Malaspina H, Devlin S, Esquirol A, Giralt S, Jakubowski AA, Caballero D, Maloy M, Papadopoulos EB, Piñana JL, Fox ML, Márquez F, et al. CD34+ Selection Vs. Reduced-Intensity Conditioning and Unmodified Graft for Allogeneic Hematopoietic Cell Transplantation in Patients with AML and MDS > 50 Years. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. PMID 29305194 DOI: 10.1016/J.Bbmt.2017.12.804 |
0.523 |
|
| 2018 |
Landau HJ, Shah GL, Reeds M, Hilden P, Andrejko M, Applebaum A, Batalha J, Cazeau N, Chung DJ, Cortes M, Jenkelowitz JG, Kiss C, Devlin SM, Lestrange N, Lynch K, et al. Homebound Autologous Hematopoietic Cell Transplantation for Plasma Cell Disorders in an Urban Setting Is Safe for Patients and Preferred By Patients and Caregivers Blood. 132: 2258-2258. DOI: 10.1182/Blood-2018-99-120049 |
0.445 |
|
| 2018 |
Rodriguez LB, Shah GL, Knezevic A, Devlin SM, Maloy M, Koehne G, Chung DJ, Landau HJ, Giralt S. Impact of CD34 Cell Dose Infused on the Duration of Absolute Neutropenia after High Dose Melphalan and Autologous HCT for Myeloma Blood. 132: 2156-2156. DOI: 10.1182/Blood-2018-99-119537 |
0.317 |
|
| 2018 |
Bolton K, Ptashkin R, Braunstein L, Kelly D, Devlin SM, Coombs CC, Moarii M, Patel M, Bernard E, Berthon A, Glodzik D, Walsh MF, Mandelker D, Patel A, Schulman J, et al. Oncologic Therapy for Solid Tumors Alters the Risk of Clonal Hematopoiesis Blood. 132: 747-747. DOI: 10.1182/Blood-2018-99-119530 |
0.333 |
|
| 2018 |
Pianko MJ, Devlin SM, Littmann ER, Chansakul A, Mastey D, Salcedo M, Fontana E, Ling L, Tavitian E, Slingerland JB, Slingerland AE, Clurman A, Gomes AL, Taur Y, Pamer EG, et al. Intestinal Microbiota Composition Is Associated with Minimal Residual Disease Negativity in Patients with Multiple Myeloma Blood. 132: 3167-3167. DOI: 10.1182/Blood-2018-99-117719 |
0.465 |
|
| 2018 |
Korde N, Mastey D, Mailankody S, Hassoun H, Lesokhin AM, Smith EL, Lendvai N, Hultcrantz M, Tavitian E, Salcedo M, Sams A, Diab V, Chung DJ, Scordo M, Lahoud OB, ... ... Devlin SM, et al. MRD-Response Driven Phase I/II Study for Newly Diagnosed Multiple Myeloma Patients Using Higher Doses of Twice-Weekly Carfilzomib (45 and 56 mg/m2) in Combination with Lenalidomide and Dexamethasone Blood. 132: 1983-1983. DOI: 10.1182/Blood-2018-99-117120 |
0.38 |
|
| 2018 |
Mazis C, Politikos I, Devlin SM, Maloy M, Davis E, Cooper C, Nhaissi M, Suri B, Wells D, Giralt S, Shah GL, Brink MRMvd, Kernan NA, Scaradavou A, Barker J. Evaluation of Cord Blood (CB) Unit TNC & CD34+ Cell Content & Donor-Recipient High-Resolution 8 HLA-Allele Match By Patient Ancestry: An Evaluation of 513 CB Units in a Racially & Ethnically Diverse Population of Adults with Hematologic Malignancies Blood. 132: 3342-3342. DOI: 10.1182/Blood-2018-99-116598 |
0.381 |
|
| 2018 |
Politikos I, Devlin SM, Maloy M, Mazis C, Naputo K, Afuye AO, Scaradavou A, Avecilla ST, Castro-Malaspina HR, Cho C, Dahi PB, Giralt S, Gyurkocza B, Jakubowski AA, Papadopoulos EB, et al. A High Degree of Engrafting Unit-Recipient HLA-Allele Mismatch Is Not Associated with an Increased Risk of Transplant-Related Mortality (TRM) or Inferior Progression-Free Survival (PFS) after Double Unit Cord Blood (CB) Transplantation (dCBT) in Adults with Hematologic Malignancies Blood. 132: 3470-3470. DOI: 10.1182/Blood-2018-99-116477 |
0.481 |
|
| 2018 |
Politikos I, Devlin SM, Mazis C, Maloy M, Naputo K, Afuye AO, Bhatt V, Scaradavou A, O'Reilly RJ, Avecilla ST, Castro-Malaspina HR, Cho C, Dahi PB, Giralt S, Gyurkocza B, et al. Double-Unit Cord Blood (CB) Transplantation with Haplo-Identical CD34+ Cells (haplo-dCBT) May Speed Neutrophil Recovery Although Successful Bridging Is Contingent on Close Haplo-Winning CB Unit HLA-Match Blood. 132: 2078-2078. DOI: 10.1182/Blood-2018-99-116276 |
0.46 |
|
| 2018 |
Shah GL, Seier K, Devlin SM, Chung DJ, Scordo M, Hultcrantz M, Korde N, Lendvai N, Lesokhin AM, Mailankody S, Smith EL, Landgren O, Landau HJ, Giralt S. Depth of Response and Outcomes in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation Blood. 132: 4619-4619. DOI: 10.1182/Blood-2018-99-116014 |
0.423 |
|
| 2018 |
Scordo M, Shah GL, Preston EV, Rodriguez N, Lin A, Maloy M, Mastrogiacomo B, Carlow D, Schofield R, Knezevic A, Devlin SM, Landau HJ, Chung DJ, Peled JU, Buchan ML, et al. Dysgeusia Is Associated with Higher Melphalan Pharmacokinetic Levels and Results in Poorer Caloric Intake and Worse Symptom Burden after Autologous Stem Cell Transplantation for Multiple Myeloma Blood. 132: 2136-2136. DOI: 10.1182/Blood-2018-99-114715 |
0.415 |
|
| 2018 |
Rampal RK, Verstovsek S, Devlin SM, Stein EM, Kadia TM, Mauro MJ, Pemmaraju N, Alvarez K, Ard N, Goodman T, Marek K, Bose P. Safety and Efficacy of Combined Ruxolitinib and Thalidomide in Patients with Myelofibrosis: Initial Results of a Phase II Study Blood. 132: 354-354. DOI: 10.1182/Blood-2018-99-114125 |
0.357 |
|
| 2018 |
Rustad EH, Hultcrantz M, Yellapantula VD, Akhlaghi T, Ho C, Arcila ME, Roshal M, Patel A, Devlin SM, Jacobsen A, Huang Y, Miller JE, Papaemmanuil E, Landgren O. V(D)J Sequence Capture for DNA-Based Minimal Residual Disease Detection in Multiple Myeloma Blood. 132: 4444-4444. DOI: 10.1182/Blood-2018-99-113889 |
0.302 |
|
| 2018 |
Lin RJ, Elko TA, Devlin SM, Jakubowski AA, Shahrokni A, Dahi PB, Perales M, Tamari R, Shaffer BC, Sauter CS, Papadopoulos EB, Castro-Malaspina HR, Barker J, Maloy M, Korc-Grodzicki B, et al. A Simple Geriatric Vulnerability Index for Older Patients Undergoing Allogeneic Hematopoietic Cell Transplantation Blood. 132: 2176-2176. DOI: 10.1182/Blood-2018-99-113688 |
0.486 |
|
| 2018 |
Lee J, Flynn J, Maloy M, Jakubowski AA, Papadopoulos EB, Cho C, Ponce D, Sauter CS, Perales M, Devlin SM, Giralt S, Castro-Malaspina HR, Tamari R. CD34+Selected Hematopoietic Stem Cell Transplants Conditioned with a Myeloablative Regimen Is Well Tolerated and Results in Good Outcomes in Patients with Myelofibrosis Blood. 132: 4636-4636. DOI: 10.1182/Blood-2018-99-113166 |
0.467 |
|
| 2018 |
Goldberg AD, Famulare C, Devlin SM, Farnoud N, Menghrajani K, Patel M, Cai S, Dunbar A, Epstein-Peterson ZD, McGovern E, Schulman J, Glass JL, Taylor J, Viny AD, Getta B, et al. Molecular Predictors and Current Management of Minimal Residual Disease (MRD) Following Induction Chemotherapy for Acute Myeloid Leukemia (AML) Blood. 132: 292-292. DOI: 10.1182/Blood-2018-99-112938 |
0.468 |
|
| 2018 |
Preston EV, Palazzo MA, Seier K, Devlin SM, Giralt S, Scordo M, Dahi PB, Matasar MJ, Moskowitz CH, Sauter CS, Shah GL, Perales M. Impact of Pre-Transplant Rituximab on Efficacy of Revaccination of Lymphoma Patients after Autologous Hematopoietic Stem Cell Transplantation Blood. 132: 4592-4592. DOI: 10.1182/Blood-2018-99-112509 |
0.493 |
|
| 2018 |
Pianko MJ, Tiutan T, Flynn J, Devlin SM, Jaffer-Sathick I, Rossi AC, Salvatore SP, Landau HJ, Lendvai N, Smith EL, Korde N, Mailankody S, Lesokhin AM, Hultcrantz M, Chung DJ, et al. Treatment Outcomes in Monoclonal Immunoglobulin Deposition Disease (MIDD): A Two Center Experience Blood. 132: 5591-5591. DOI: 10.1182/Blood-2018-99-112110 |
0.386 |
|
| 2018 |
Khan N, Peled JU, Gomes AL, Devlin SM, Rondon-Clavo C, Clurman A, Slingerland JB, Slingerland AE, Maloy M, Sung AD, Chao NJ, Sauter CS, Landau HJ, Ponce D, Gyurkocza B, et al. Loss of Microbiota Diversity after Autologous Stem Cell Transplant Is Comparable to Injury in Allogeneic Stem Cell Transplant Blood. 132: 608-608. DOI: 10.1182/Blood-2018-99-110857 |
0.513 |
|
| 2018 |
Fonseca M, Jakubowski AA, Devlin SM, Young JW, Fatmi SA, Maloy M, Giralt S, Ponce D, Markova A. HLA-a*0101 Expression Correlates with Increased Risk of Severe Cutaneous Acute Graft-Versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation Blood. 132: 4564-4564. DOI: 10.1182/Blood-2018-99-110405 |
0.45 |
|
| 2018 |
Markey KA, Gomes AL, Littmann ER, Devlin SM, Slingerland AE, Slingerland JB, Clurman A, Moore G, Fatmi SA, Maloy M, Pamer EG, Taur Y, Giralt S, Perales M, Ponce D, et al. Pre-Transplant and Peri-d100 Gastrointestinal Dysbiosis Is Associated with the Subsequent Development of Chronic Graft-Versus-Host Disease Blood. 132: 359-359. DOI: 10.1182/Blood-2018-99-110309 |
0.504 |
|
| 2018 |
Klager SA, Devlin SM, Hannum M, Jakubowski AA, Markova A. Rash in Patients after T-Cell-Depleted Peripheral Blood Stem Cell Transplantation: Eosinophilia and Pruritus Do Not Distinguish Acute Graft-Versus-Host Disease from Drug Rash Blood. 132: 4570-4570. DOI: 10.1182/Blood-2018-99-110307 |
0.466 |
|
| 2018 |
Shah GL, Landau H, Sarubbi C, Schofield R, Lin A, Bhatt V, Harnicar S, Devlin SM, Castro-Malaspina H, Chung DJ, Dahi PB, Gyurkocza B, Koehne G, Matasar MJ, Moskowitz CH, et al. Pharmacokinetics and Toxicities after Evomela® (Propylene Glycol Free Melphalan) with Hematopoietic Stem Cell Transplant (HCT) for Multiple Myeloma (MM), AL Amyloidosis (AL), Lymphoma, Acute Myeloid Leukemia (AML), and Myelodysplastic Syndrome (MDS) Biology of Blood and Marrow Transplantation. 24. DOI: 10.1016/J.Bbmt.2017.12.664 |
0.416 |
|
| 2018 |
Lau C, Politikos I, Devlin SM, Jacob AG, Maloy M, Naputo K, Afuye A, Bhatt V, Dahi PB, Perales M, Giralt SA, O'Reilly RJ, Ponce DM, Prockop SE, Shah GL, et al. Analysis of Cytomegalovirus (CMV) Infections in the First 180 Days in Adult Sero-Positive Cord Blood Transplantation (CBT) Recipients Reveals High Infection Rates and Treatment Burden Biology of Blood and Marrow Transplantation. 24. DOI: 10.1016/J.Bbmt.2017.12.465 |
0.356 |
|
| 2018 |
Preston EV, Malard F, Seier K, Cho C, Devlin SM, Maloy M, Borrill T, Palazzo M, Smith K, Maslak P, Brink MRMvd, Shah GL, Perales M. Rituximab Use, Immune Reconstitution, and Vaccination after Ex-Vivo CD34-Selected Myeloablative Allogeneic Hematopoietic Cell Transplantation (HCT) Biology of Blood and Marrow Transplantation. 24. DOI: 10.1016/J.Bbmt.2017.12.437 |
0.381 |
|
| 2018 |
Berman E, Assal A, Maloy M, Zheng J, Devlin SM, Papadopoulos EB, Jakubowski AA. Role of Consolidation Therapy Prior to CD34− Selected Allogeneic Stem Cell Transplantation for Adult Patients with Acute Myeloid Leukemia in First Remission Biology of Blood and Marrow Transplantation. 24. DOI: 10.1016/J.Bbmt.2017.12.360 |
0.471 |
|
| 2018 |
Root JC, Rocha-Cadman X, Kasven-Gonzalez N, Campbell C, Maloy M, Flynn J, Devlin SM, Jakubowski AA. Pre-Transplant Cognitive Dysfunction in Hematologic Cancers, Predictors and Associated Outcomes Biology of Blood and Marrow Transplantation. 24. DOI: 10.1016/J.Bbmt.2017.12.354 |
0.353 |
|
| 2018 |
Bryant A, Devlin SM, Castro-Malaspina H, Jakubowski AA, Maloy M, Papadopoulos EB, Giralt SA, Perales M. Efficacy of Donor Lymphocyte Infusion in CD34+ Selected Allogeneic Hematopoietic Stem Cell Transplant for Myeloid and Lymphoid Malignancies: A Single Center Experience Biology of Blood and Marrow Transplantation. 24. DOI: 10.1016/J.Bbmt.2017.12.349 |
0.452 |
|
| 2018 |
Bhatt V, Politikos I, Devlin SM, Jacob AG, Maloy M, Naputo K, Afuye A, Scaradavou A, O'Reilly RJ, Castro-Malaspina H, Dahi PB, Giralt SA, Gyurkocza B, Jakubowski AA, Papadopoulos EB, et al. Therapeutic Cyclosporine-a (CSA) Levels in the First 7 Days after Cord Blood Transplantation (CBT) Are Critical to Prevent Severe Acute Graft-Versus-Host Disease (aGVHD) Biology of Blood and Marrow Transplantation. 24. DOI: 10.1016/J.Bbmt.2017.12.298 |
0.413 |
|
| 2018 |
Politikos I, Devlin SM, Jacob AG, Maloy M, Mazis C, Naputo K, Afuye A, Scaradavou A, O'Reilly RJ, Avecilla ST, Castro-Malaspina H, Dahi PB, Giralt SA, Gyurkocza B, Jakubowski AA, et al. Long-Term Follow-Up of Adult Double Unit Cord Blood (CB) Transplantation (dCBT) Recipients Reveals High Rates of Progression-Free Survival after a Novel Cy/ Flu/ Thio/ TBI 400 Intermediate Intensity Conditioning Regimen Biology of Blood and Marrow Transplantation. 24: S187-S188. DOI: 10.1016/J.Bbmt.2017.12.297 |
0.408 |
|
| 2018 |
Lin RJ, Perales M, Shahrokni A, Maloy M, Devlin SM, Jakubowski AA, Dahi PB, Shah GL, Korc-Grodzicki B, Giralt SA. Prevalence of Functional Impairment and Geriatric Vulnerability during Pre-Transplant Geriatric Assessment in an Academic Hematopoietic Cell Transplantation Center Biology of Blood and Marrow Transplantation. 24. DOI: 10.1016/J.Bbmt.2017.12.259 |
0.428 |
|
| 2018 |
Pathak P, Shah GL, Tsyvkin E, Maloy M, Knezevic A, Devlin SM, Giralt SA, Matasar MJ, Moskowitz CH, Sauter CS, Perales M. Transformed Indolent Lymphoma Outcomes Similar to De Novo Diffuse Large B-Cell Lymphoma after Autologous Hematopoietic Stem Cell Transplantation (AHCT), but Not Allogeneic HCT (Allo-HCT) Biology of Blood and Marrow Transplantation. 24. DOI: 10.1016/J.Bbmt.2017.12.231 |
0.423 |
|
| 2018 |
Cho C, Maloy M, Devlin SM, Aras O, Castro-Malaspina H, Dauer LT, Jakubowski AA, O'Reilly RJ, Papadopoulos EB, Perales M, Rappaport TS, Tamari R, van den Brink MR, Giralt SA. Characterizing Ionizing Radiation Exposure after T-Cell Depleted Allogeneic Hematopoietic Cell Transplantation Biology of Blood and Marrow Transplantation. 24: S252-S253. DOI: 10.1016/J.Bbmt.2017.12.182 |
0.389 |
|
| 2018 |
Bachier-Rodriguez L, Shah GL, Knezevic A, Devlin SM, Maloy M, Koehne G, Chung DJ, Landau H, Giralt SA. Engraftment Kinetics after High-Dose Melphalan Autologous Stem Cell Transplant in Patients with Multiple Myeloma Biology of Blood and Marrow Transplantation. 24. DOI: 10.1016/J.Bbmt.2017.12.096 |
0.476 |
|
| 2018 |
Dahi PB, Clavo CR, Maloy M, Seier K, Devlin SM, Robinson K, Scordo M, Shah GL, Tamari R, Matasar MJ, Hamlin P, Jakubowski AA, Sauter CS, Moskowitz CH, Giralt SA. Toxicities Associated with High Dose Chemotherapy and Autologous Stem Cell Transplantation in Older Patients with Non-Hodgkin Lymphoma Biology of Blood and Marrow Transplantation. 24. DOI: 10.1016/J.Bbmt.2017.12.075 |
0.479 |
|
| 2018 |
Shah GL, Lin A, Schofield R, Sarubbi C, Preston EV, Devlin SM, Bhatt V, Harnicar S, Hoover E, Chung DJ, Dahi PB, Koehne G, Tamari R, Wang P, Giese R, et al. Feasibility and Toxicity of Pharmacokinetic (PK)-Directed Dosing of Evomela® (propylene glycol free melphalan, PGF-MEL) for Multiple Myeloma (MM) and AL Amyloidosis (AL) Patients Undergoing Autologous Hematopoietic Stem Cell Transplant (AHCT) Biology of Blood and Marrow Transplantation. 24. DOI: 10.1016/J.Bbmt.2017.12.072 |
0.424 |
|
| 2018 |
Cho C, Flynn J, Devlin SM, Maloy M, Giralt SA, Koehne G, Maslak P, O'Reilly RJ, Smith K, Tonon J, Avecilla ST, Perales M. Universal Engraftment after Allogeneic HCT Using Cryopreserved CD34+ Cell-Selected Grafts Biology of Blood and Marrow Transplantation. 24: S209. DOI: 10.1016/J.Bbmt.2017.12.046 |
0.368 |
|
| 2017 |
Davis E, Devlin S, Cooper C, Nhaissi M, Paulson J, Wells D, Scaradavou A, Giralt S, Papadopoulos E, Kernan NA, Byam C, Barker JN. Validation of an Algorithm to Predict the Likelihood of an 8/8 HLA-Matched Unrelated Donor at Search Initiation. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. PMID 29287807 DOI: 10.1016/J.Bbmt.2017.12.791 |
0.388 |
|
| 2017 |
Coombs C, Kuk D, Devlin S, Siegelbaum RH, Durack JC, Parameswaran R, Mantha S, Deng K, Soff G. Outcomes after inferior vena cava filter placement in cancer patients diagnosed with pulmonary embolism: risk for recurrent venous thromboembolism. Journal of Thrombosis and Thrombolysis. PMID 28993967 DOI: 10.1007/S11239-017-1557-2 |
0.301 |
|
| 2017 |
Cho C, Hsu M, Barba P, Maloy MA, Avecilla ST, Barker JN, Castro-Malaspina H, Giralt SA, Jakubowski AA, Koehne G, Meagher RC, O'Reilly RJ, Papadopoulos EB, Ponce DM, Tamari R, ... ... Devlin SM, et al. Long-term prognosis for 1-year relapse-free survivors of CD34+ cell-selected allogeneic hematopoietic stem cell transplantation: a landmark analysis. Bone Marrow Transplantation. PMID 28991247 DOI: 10.1038/Bmt.2017.197 |
0.498 |
|
| 2017 |
Shah GL, Scordo M, Kosuri S, Herrera DA, Cho C, Maloy MA, Nieves J, Devlin SM, Borrill T, Carlow DC, Avecilla ST, Meagher RC, O'Reilly RJ, Jakubowski AA, Papadopoulos EB, et al. Impact of Toxicity on Survival for Older Adult Patients after CD34+ Selected Allogeneic Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. PMID 28951193 DOI: 10.1016/J.Bbmt.2017.08.040 |
0.498 |
|
| 2017 |
Scordo M, Shah GL, Kosuri S, Herrera DA, Cho C, Devlin SM, Maloy MA, Nieves J, Borrill T, Avecilla ST, Meagher RC, Carlow DC, O'Reilly RJ, Papadopoulos EB, Jakubowski AA, et al. The Effects of Late Toxicities on Outcomes in Long-Term Survivors of Ex-Vivo CD34+-Selected Allogeneic Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. PMID 28870777 DOI: 10.1016/J.Bbmt.2017.08.033 |
0.437 |
|
| 2017 |
Coombs CC, Zehir A, Devlin SM, Kishtagari A, Syed A, Jonsson P, Hyman DM, Solit DB, Robson ME, Baselga J, Arcila ME, Ladanyi M, Tallman MS, Levine RL, Berger MF. Therapy-Related Clonal Hematopoiesis in Patients with Non-hematologic Cancers Is Common and Associated with Adverse Clinical Outcomes. Cell Stem Cell. PMID 28803919 DOI: 10.1016/J.Stem.2017.07.010 |
0.315 |
|
| 2017 |
Kosuri S, Herrera DA, Scordo M, Shah GL, Cho C, Devlin SM, Maloy MA, Nieves J, Borrill T, Carlow DC, Avecilla ST, Meagher RC, O'Reilly RJ, Papadopoulos EB, Jakubowski AA, et al. The Impact of Toxicities on First Year Outcomes after Ex-Vivo CD34+ Selected Allogeneic Hematopoietic Cell Transplantation in Adults with Hematologic Malignancies. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. PMID 28733264 DOI: 10.1016/J.Bbmt.2017.07.012 |
0.479 |
|
| 2017 |
Hassoun H, Roshal M, Sabari J, Nguyen J, Gao Q, Devlin SM, Landau H, Lendvai N, Chung DJ, Lesokhin AM, Korde N, Mailankody S, Dogan A, Giralt SA, Landgren CO. Immunophenotypic evidence for reactive polyclonal marrow plasmacytosis in multiple myeloma patients receiving lenalidomide maintenance. Leukemia & Lymphoma. 1-4. PMID 28482750 DOI: 10.1080/10428194.2017.1312382 |
0.405 |
|
| 2017 |
Getta BM, Devlin SM, Levine RL, Arcila ME, Mohanty AS, Zehir A, Tallman MS, Giralt SA, Roshal M. Multicolor Flow Cytometry and Multi-Gene Next Generation Sequencing are Complementary and Highly Predictive for Relapse in Acute Myeloid Leukemia Following Allogeneic Transplant. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. PMID 28315400 DOI: 10.1016/J.Bbmt.2017.03.017 |
0.399 |
|
| 2017 |
Peled JU, Devlin SM, Staffas A, Lumish M, Khanin R, Littmann ER, Ling L, Kosuri S, Maloy M, Slingerland JB, Ahr KF, Porosnicu Rodriguez KA, Shono Y, Slingerland AE, Docampo MD, et al. Intestinal Microbiota and Relapse After Hematopoietic-Cell Transplantation. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2016703348. PMID 28296584 DOI: 10.1200/Jco.2016.70.3348 |
0.468 |
|
| 2017 |
Kosuri S, Wolff T, Devlin SM, Byam C, Mazis CM, Naputo K, Davis E, Paulson J, Nhaissi M, Wells DS, Dahi P, Giralt SA, Jakubowski A, Perales MA, Shaffer BC, et al. Prospective Evaluation of Unrelated Donor Cord Blood and Haploidentical Donor Access Reveals Graft Availability Varies by Patient Ancestry: Practical Implications for Donor Selection. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. PMID 28263918 DOI: 10.1016/J.Bbmt.2017.03.001 |
0.467 |
|
| 2017 |
Geyer MB, Hsu M, Devlin SM, Tallman MS, Douer D, Park JH. Overall survival among older U.S. adults with ALL remains low despite modest improvement since 1980: SEER analysis. Blood. PMID 28122741 DOI: 10.1182/Blood-2016-11-749507 |
0.363 |
|
| 2017 |
Glezerman IG, Devlin S, Maloy M, Bui M, Jaimes EA, Giralt SA, Jakubowski AA. Long term renal survival in patients undergoing T-Cell depleted versus conventional hematopoietic stem cell transplants. Bone Marrow Transplantation. PMID 28092350 DOI: 10.1038/Bmt.2016.343 |
0.445 |
|
| 2017 |
Mantha S, Goldman DA, Devlin SM, Lee JW, Zannino D, Collins M, Douer D, Iland HJ, Litzow MR, Stein EM, Appelbaum FR, Larson RA, Stone R, Powell BL, Geyer S, et al. Determinants of fatal bleeding during induction therapy for acute promyelocytic leukemia in the ATRA era. Blood. PMID 28082441 DOI: 10.1182/Blood-2016-10-747170 |
0.379 |
|
| 2017 |
Shah GL, Landau H, Londono D, Devlin SM, Kosuri S, Lesokhin AM, Lendvai N, Hassoun H, Chung DJ, Koehne G, Jhanwar SC, Landgren O, Levine R, Giralt SA. Gain of chromosome 1q portends worse prognosis in multiple myeloma despite novel agent-based induction regimens and autologous transplantation. Leukemia & Lymphoma. 1-9. PMID 28078910 DOI: 10.1080/10428194.2016.1260126 |
0.382 |
|
| 2017 |
Koehne G, Devlin S, Chung DJ, Landau HJ, Korde N, Mailankody S, Hassoun H, Lesokhin AM, Lendvai N, Giralt S, Landgren CO. WT1 heteroclitic epitope immunization following autologous stem cell transplantation in patients with high-risk multiple myeloma (MM). Journal of Clinical Oncology. 35: 8016-8016. DOI: 10.1200/Jco.2017.35.15_Suppl.8016 |
0.401 |
|
| 2017 |
Soff GA, Miao Y, Devlin SM, Mantha S, Mones JV, Li VJ, Abou-Alfa GK, Cercek A, Kemeny N, Parameswaran R. Romiplostim for Chemotherapy-Induced Thrombocytopenia (CIT). Results of a Phase 2 Trial Blood. 130: 289-289. DOI: 10.1182/Blood.V130.Suppl_1.289.289 |
0.398 |
|
| 2017 |
Shah GL, Lin A, Schofield R, Sarubbi C, Preston EV, Devlin SM, Bhatt V, Harnicar SJ, Hoover E, Chung DJ, Dahi PB, Koehne G, Tamari R, Carlow D, Giralt SA, et al. Feasibility, Tolerability, and Patient-Reported Outcomes with Pharmacokinetic (PK)-Directed Dosing of Evomela® (propylene glycol free melphalan) for Multiple Myeloma and AL Amyloidosis Patients Undergoing Autologous Hematopoietic Stem Cell Transplant (AHCT) Blood. 130: 2023-2023. DOI: 10.1182/Blood.V130.Suppl_1.2023.2023 |
0.387 |
|
| 2017 |
Goldberg AD, Horvat TZ, Hsu M, Devlin SM, Cuello BM, Daley RJ, King AC, Buie LW, Glass JL, Mauro MJ, Stein EM, Berman E, Klimek VM, Tallman MS. Venetoclax Combined with Either a Hypomethylating Agent or Low-Dose Cytarabine Shows Activity in Relapsed and Refractory Myeloid Malignancies Blood. 130: 1353-1353. DOI: 10.1182/Blood.V130.Suppl_1.1353.1353 |
0.446 |
|
| 2017 |
Koehne G, Devlin S, Korde N, Mailankody S, Heather L, Hassoun H, Lesokhin A, Lendvai N, Chung D, Sarlis N, Giralt S, Landgren O. Galinpepimut-S, a WT1-Targeting Immuno-Oncology Treatment, Induces Specific, Robust and Durable Immune Responses (IRs) in Patients (Pts) with High-Risk (HR) Multiple Myeloma (MM) Clinical Lymphoma Myeloma and Leukemia. 17: S343-S344. DOI: 10.1016/J.Clml.2017.07.164 |
0.32 |
|
| 2017 |
Shah G, Assal A, Hsu M, Devlin S, Hassoun H, Korde N, Lendvai N, Lesokhin A, Mailankody S, Smith E, Chung D, Koehne G, Landgren CO, Landau H, Giralt S. Improvement of Response for Multiple Myeloma patients on Lenalidomide Maintenance after Autologous Hematopoietic Stem Cell Transplantation (Auto HCT) Clinical Lymphoma, Myeloma & Leukemia. 17. DOI: 10.1016/J.Clml.2017.03.253 |
0.482 |
|
| 2017 |
Shah G, Palazzo M, Copelan O, Seier K, Devlin S, Hassoun H, Korde N, Lendvai N, Lesokhin A, Mailankody S, Chung D, Koehne G, Landgren CO, Landau H, Giralt S, et al. Re-immunization following Autologous Hematopoietic Stem Cell Transplantation (Auto HCT) is Safe and Effective in Patients with Multiple Myeloma Receiving Lenalidomide Maintenance Clinical Lymphoma, Myeloma & Leukemia. 17. DOI: 10.1016/J.Clml.2017.03.149 |
0.48 |
|
| 2017 |
Shah GL, Scordo M, Kosuri S, Herrera DAA, Cho C, Maloy M, Nieves J, Devlin SM, Borrill T, Carlow D, Avecilla ST, Meagher R, O'Reilly RJ, Koehne G, Shaffer B, et al. Comparable Survival with Organ Toxicity Predicting for Overall Survival (OS) and Non-Relapse Mortality (NRM) in Older Adult Patients after CD34+ Selected Allogeneic Hematopoietic Stem Cell Transplantation (Allo-HCT) Biology of Blood and Marrow Transplantation. 23: S96-S97. DOI: 10.1016/J.Bbmt.2017.01.039 |
0.464 |
|
| 2017 |
Davis E, Devlin SM, Cooper C, Nhaissi M, Paulson J, Wells DS, Scaradavou A, Giralt SA, Papadopoulos EB, Kernan NA, Byam C, Barker JN. Using Haplogictm & Recipient Ancestry: The Likelihood of Identifying an 8/8 HLA-Matched Unrelated Donor Can be Accurately Predicted at the Time of the Preliminary Search Markedly Improving Search Efficiency & Speed to Allograft: An 830 Patient Analysis Biology of Blood and Marrow Transplantation. 23. DOI: 10.1016/J.Bbmt.2017.01.023 |
0.381 |
|
| 2017 |
Greenberg D, Shah GL, Maloy M, Devlin SM, Giralt SA, Perales M, Feldman DR. The Hematopoietic Cell Transplantation Comorbidity Index (HCT-CI) is Not Predictive of Outcomes in Germ Ce Cancer Patients Receiving Autologous Transplantation Biology of Blood and Marrow Transplantation. 23. DOI: 10.1016/J.Bbmt.2016.12.517 |
0.483 |
|
| 2017 |
Palazzo M, Shah GL, Copelan O, Seier K, Devlin SM, Hassoun H, Korde NS, Lendvai N, Lesokhin AM, Mailankody S, Chung DJ, Koehne G, Landgren O, Landau H, Giralt SA, et al. Safety and Efficacy of Re-Immunization with Inactivated Vaccines in Multiple Myeloma Patients on Lenalidomide Maintenance Following Autologous Hematopoietic Stem Cell Transplantation (Auto HCT) Biology of Blood and Marrow Transplantation. 23. DOI: 10.1016/J.Bbmt.2016.12.444 |
0.411 |
|
| 2017 |
Shah GL, Assal A, Hsu M, Devlin SM, Hassoun H, Korde NS, Lendvai N, Lesokhin AM, Mailankody S, Smith E, Chung DJ, Koehne G, Landgren O, Landau H, Giralt SA. Depth and Timing of Improvement of Response for Multiple Myeloma Patients on Lenalidomide Maintenance after Autologous Hematopoietic Stem Cell Transplantation (Auto HCT) Biology of Blood and Marrow Transplantation. 23. DOI: 10.1016/J.Bbmt.2016.12.437 |
0.479 |
|
| 2017 |
Sola M, Devlin SM, Maloy M, Dierov D, Barker JN, Castro-Malaspina H, Dahi P, Jakubowski AA, Koehne G, Papadopoulos EB, Sauter CS, Tamari R, Brink MRMvd, Young JW, Giralt SA, et al. Graft-Versus Host Disease (GVHD Status and Severity Mediate Late Effects of Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in a 1-Year Landmark Analysis Biology of Blood and Marrow Transplantation. 23. DOI: 10.1016/J.Bbmt.2016.12.406 |
0.458 |
|
| 2017 |
Scordo M, Shah GL, Kosuri S, Herrera DA, Cho C, Devlin SM, Maloy M, Nieves J, Borrill T, Carlow D, Avecilla ST, Meagher R, O'Reilly RJ, Koehne G, Gyurkocza B, et al. Post-Transplant Toxicities and Outcomes in Long-Term Survivors of Ex-Vivo CD34+ Selected Allogeneic Hematopoietic Cell Transplantation Biology of Blood and Marrow Transplantation. 23: S228-S229. DOI: 10.1016/J.Bbmt.2016.12.405 |
0.446 |
|
| 2017 |
Lau C, Bhatt V, Dahi P, Devlin SM, Yoo Y, Adel NG, Mazis C, Perales M, Giralt SA, Koehne G, Ponce DM, Papanicolaou GA, Barker JN. Incidence, Severity, Day 100 Treatment Efficacy and Therapy Toxicity of Cytomegalovirus (CMV) Infections with Early Pre-Emptive Therapy in Adult Cord Blood (CB) Transplant Recipients Biology of Blood and Marrow Transplantation. 23. DOI: 10.1016/J.Bbmt.2016.12.371 |
0.386 |
|
| 2017 |
Cho C, Hilden P, Politikos I, Borrill T, Ciolino C, Devlin SM, Maloy M, Smith K, Giralt SA, O'Reilly RJ, van den Brink MR, Perales M. CMV Seropositivity and Viremia Drive T-Cell Reconstitution after CD34-Selected Allogeneic HCT Biology of Blood and Marrow Transplantation. 23: S162-S163. DOI: 10.1016/J.Bbmt.2016.12.344 |
0.329 |
|
| 2017 |
Politikos I, Devlin SM, Mazis C, Maloy M, Scaradavou A, Dahi P, Perales M, Giralt SA, Ponce DM, Barker JN. A Novel Intermediate Intensity Conditioning Regimen Achieves High Rates of Long-Term Outpatient Progression-Free Survival Offsetting the Disadvantage of Early Post-Transplant Complications in Adult Cord Blood (CB) Transplant Recipients Biology of Blood and Marrow Transplantation. 23. DOI: 10.1016/J.Bbmt.2016.12.292 |
0.439 |
|
| 2017 |
Boughan KM, Dahi P, Devlin SM, Byam C, Yoo Y, Mazis C, Davis E, Nhaissi M, Paulson J, Wells DS, Cooper C, Ponce DM, Giralt SA, Papadopoulos EB, Kernan NA, et al. Despite Increasing Size of Unrelated Donor (URD) Registries and the Global CB Inventory Racial Disparities in Access to URD and CB Grafts Persist: A Prospective 10 Year Analysis of 1,112 Patients Biology of Blood and Marrow Transplantation. 23. DOI: 10.1016/J.Bbmt.2016.12.283 |
0.402 |
|
| 2017 |
Shah GL, Scordo M, Devlin SM, Yahalom J, Matasar MJ, Moskowitz A, Giralt SA, Moskowitz CH. Early Toxicities Associated with Radiation Based Conditioning for Relapsed/Refractory Hodgkin Lymphoma Patients Undergoing High Dose Therapy and Autologous Stem Cell Transplantation (HDT-ASCT) Biology of Blood and Marrow Transplantation. 23. DOI: 10.1016/J.Bbmt.2016.12.264 |
0.456 |
|
| 2017 |
Scordo M, Shah GL, Kosuri S, Herrera DAA, Hsu M, Devlin SM, Maloy M, Nieves J, Borrill T, Avecilla ST, Meagher R, O'Reilly RJ, Koehne G, Gyurkocza B, Castro-Malaspina H, et al. Immune-Mediated Hemolytic Anemia (IMHA) and Immune Thrombocytopenia (ITP) after Ex-Vivo CD34+ Selected Allogeneic Hematopoietic Stem Cell Transplantation Biology of Blood and Marrow Transplantation. 23: S129-S130. DOI: 10.1016/J.Bbmt.2016.12.243 |
0.392 |
|
| 2017 |
Lin A, Drill E, Proli AJ, Beyer K, Bhatt V, Devlin SM, Koehne G. Impact of Busulfan Exposure on Transplant Outcomes for Patients with Relapsed Multiple Myeloma Undergoing CD34-Selected Allogeneic Hematopoietic Stem Cell Transplant Biology of Blood and Marrow Transplantation. 23. DOI: 10.1016/J.Bbmt.2016.12.200 |
0.485 |
|
| 2017 |
Kosuri S, Herrera DAA, Scordo M, Shah GL, Devlin SM, Maloy M, Nieves J, Cho C, Borrill T, Carlow D, Avecilla ST, Meagher R, O'Reilly RJ, Koehne G, Gyurkocza B, et al. Toxicities and Outcomes in the First Year after Ex-Vivo CD34+ Selected Allogeneic Hematopoietic Cell Transplantation in Adults with Hematologic Malignancies Biology of Blood and Marrow Transplantation. 23: S286-S287. DOI: 10.1016/J.Bbmt.2016.12.196 |
0.438 |
|
| 2017 |
Cho C, Devlin SM, Maloy M, Horowitz MM, Rizzo JD, Giralt SA, Perales M. Application of the CIBMTR Survival Outcomes Calculator to CD34-Selected Allogeneic HCT for Acute Leukemia and Myelodysplastic Syndrome Biology of Blood and Marrow Transplantation. 23. DOI: 10.1016/J.Bbmt.2016.12.012 |
0.337 |
|
| 2016 |
Barba P, Hilden P, Devlin SM, Maloy M, Dierov D, Nieves J, Garrett MD, Sogani J, Cho C, Barker JN, Kernan NA, Castro-Malaspina H, Jakubowski AA, Koehne G, Papadopoulos EB, et al. Ex Vivo CD34+ Selected T-Cell Depleted (TCD) Peripheral Blood Stem Cell Grafts for Allogeneic Hematopoietic Stem Cell Transplantation in Acute Leukemia and Myelodysplastic Syndrome is Associated with Low Incidence of Acute and Chronic Graft-Versus-Host Disease (GVHD) and High Treatment Response. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. PMID 28017734 DOI: 10.1016/J.Bbmt.2016.12.633 |
0.509 |
|
| 2016 |
Barba P, Ratan R, Cho C, Ceberio I, Hilden P, Devlin SM, Maloy MA, Barker JN, Castro-Malaspina H, Jakubowski AA, Koehne G, Papadopoulos EB, Ponce DM, Sauter C, Tamari R, et al. The Hematopoietic Cell Transplantation Comorbidity Index (HCT-CI) Predicts Outcomes in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndromes Receiving CD34+ Selected Grafts for Allogeneic Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. PMID 27789361 DOI: 10.1016/J.Bbmt.2016.10.017 |
0.452 |
|
| 2016 |
Ogunniyi A, Rodriguez M, Devlin S, Adel N, Landau H, Chung DJ, Lendvai N, Lesokhin A, Koehne G, Mailankody S, Korde N, Reich L, Landgren O, Giralt S, Hassoun H. Upfront use of plerixafor and granulocyte-colony stimulating factor (GCSF) for stem cell mobilization in patients with multiple myeloma: efficacy and analysis of risk factors associated with poor stem cell collection efficiency. Leukemia & Lymphoma. 1-7. PMID 27735212 DOI: 10.1080/10428194.2016.1239261 |
0.392 |
|
| 2016 |
Bhatt V, Shune L, Lauer E, Lubin M, Devlin SM, Scaradavou A, Parameswaran R, Perales MA, Ponce DM, Mantha S, Kernan NA, Barker JN. Autoimmune hemolysis and immune thrombocytopenic purpura after cord blood transplantation may be life-threatening and warrants early therapy with rituximab. Bone Marrow Transplantation. PMID 27643868 DOI: 10.1038/Bmt.2016.228 |
0.487 |
|
| 2016 |
Landgren O, Devlin S, Boulad M, Mailankody S. Role of MRD status in relation to clinical outcomes in newly diagnosed multiple myeloma patients: a meta-analysis. Bone Marrow Transplantation. 51: 1565-1568. PMID 27595280 DOI: 10.1038/Bmt.2016.222 |
0.417 |
|
| 2016 |
Watts JM, Dumitriu B, Hilden P, Kishtagari A, Rapaport F, Chen C, Ahn J, Devlin SM, Stein EM, Rampal R, Levine RL, Young N, Tallman MS. Telomere length and associations with somatic mutations and clinical outcomes in acute myeloid leukemia. Leukemia Research. 49: 62-65. PMID 27568819 DOI: 10.1016/J.Leukres.2016.07.013 |
0.36 |
|
| 2016 |
Landau H, Smith M, Landry C, Chou JF, Devlin SM, Hassoun H, Bello C, Giralt S, Comenzo RL. Long-term event-free and overall survival after risk-adapted melphalan and SCT for systemic light chain amyloidosis. Leukemia. PMID 27560108 DOI: 10.1038/Leu.2016.229 |
0.422 |
|
| 2016 |
Reiss SN, Buie LW, Adel N, Goldman DA, Devlin SM, Douer D. Hypoalbuminemia is significantly associated with increased clearance time of high dose methotrexate in patients being treated for lymphoma or leukemia. Annals of Hematology. PMID 27542957 DOI: 10.1007/S00277-016-2795-7 |
0.38 |
|
| 2016 |
Coombs CC, Sallman DA, Devlin SM, Dixit S, Mohanty A, Knapp K, Al Ali NH, Lancet JE, List AF, Komrokji RS, Padron E, Arcila ME, Klimek VM, van den Brink MR, Tallman MS, et al. Mutational correlates of response to hypomethylating agent therapy in acute myeloid leukemia. Haematologica. PMID 27418649 DOI: 10.3324/Haematol.2016.148999 |
0.343 |
|
| 2016 |
Getta BM, Woo KM, Devlin S, Park JH, Abdel-Wahab O, Saven A, Rai K, Tallman MS. Treatment outcomes and secondary cancer incidence in young patients with hairy cell leukaemia. British Journal of Haematology. PMID 27351754 DOI: 10.1111/Bjh.14207 |
0.412 |
|
| 2016 |
Shono Y, Docampo MD, Peled JU, Perobelli SM, Velardi E, Tsai JJ, Slingerland AE, Smith OM, Young LF, Gupta J, Lieberman SR, Jay HV, Ahr KF, Porosnicu Rodriguez KA, Xu K, ... ... Devlin SM, et al. Increased GVHD-related mortality with broad-spectrum antibiotic use after allogeneic hematopoietic stem cell transplantation in human patients and mice. Science Translational Medicine. 8: 339ra71. PMID 27194729 DOI: 10.1126/Scitranslmed.Aaf2311 |
0.443 |
|
| 2016 |
Ganzel C, Mathews V, Alimoghaddam K, Ghavamzadeh A, Kuk D, Devlin S, Wang H, Zhang MJ, Weisdorf D, Douer D, Rowe JM, Polge E, Esteve J, Nagler A, Mohty M, et al. Autologous transplant remains the preferred therapy for relapsed APL in CR2. Bone Marrow Transplantation. PMID 27088379 DOI: 10.1038/Bmt.2016.96 |
0.496 |
|
| 2016 |
Lendvai N, Yee AJ, Tsakos I, Alexander A, Devlin SM, Hassoun H, Korde N, Lesokhin AM, Landau H, Mailankody S, Koehne G, Chung DJ, Landgren O, Raje NS, Giralt S. Phase IB study of cabozantinib in patients with relapsed and/or refractory multiple myeloma. Blood. PMID 27020089 DOI: 10.1182/Blood-2016-01-694786 |
0.453 |
|
| 2016 |
Dahi PB, Morawa E, Perales MA, Zabor EC, Devlin SM, Maloy M, Castro-Malaspina H, O'Reilly RJ, Papadopoulos EB, Jakubowski AA, Giralt SA. Low incidence of GvHD with T-cell depleted allografts facilitates further treatments for post-transplantation relapse in AML and MDS. Bone Marrow Transplantation. PMID 26926229 DOI: 10.1038/bmt.2016.23 |
0.35 |
|
| 2016 |
Lunning MA, Migliacci JC, Hilden P, Devlin SM, Castro-Malaspina H, Giralt S, Perales MA, Zelenetz AD, Moskowitz CH, Sauter CS. The potential benefit of allogeneic over autologous transplantation in patients with very early relapsed and refractory follicular lymphoma with prior remission duration of ≤12 months. British Journal of Haematology. PMID 26847389 DOI: 10.1111/Bjh.13947 |
0.505 |
|
| 2016 |
Landau H, Wood K, Chung DJ, Koehne G, Lendvai N, Hassoun H, Lesokhin A, Hoover E, Zheng J, Devlin SM, Giralt S. Fractionated stem cell infusions for patients with plasma cell myeloma undergoing autologous hematopoietic cell transplantation. Leukemia & Lymphoma. 1-5. PMID 26758672 DOI: 10.3109/10428194.2015.1121256 |
0.457 |
|
| 2016 |
Berman E, Maloy M, Devlin S, Jhanwar S, Papadopoulos E, Jakubowski A. Stem cell transplantation in adults with acute myelogenous leukemia, normal cytogenetics, and the FLT3-ITD mutation. Leukemia Research. 40: 33-7. PMID 26692109 DOI: 10.1016/J.Leukres.2015.11.010 |
0.491 |
|
| 2016 |
Geyer MB, Hsu M, Devlin S, Douer D, Park JH. Outcomes of patients 60 and older with ALL: Analysis of the SEER Database. Journal of Clinical Oncology. 34: 7021-7021. DOI: 10.1200/Jco.2016.34.15_Suppl.7021 |
0.329 |
|
| 2016 |
Zehir A, Coombs CC, Devlin S, Kishtagari A, Hyman DM, Solit DB, Robson ME, Baselga J, Arcila ME, Tallman MS, Levine RL, Berger MF. Prevalence of clonal hematopoiesis in patients with advanced cancer. Journal of Clinical Oncology. 34: 1511-1511. DOI: 10.1200/Jco.2016.34.15_Suppl.1511 |
0.314 |
|
| 2016 |
Getta BM, Devlin S, Maloy MA, Mohanty A, Arcila M, Tallman MS, Levine RL, Giralt SA, Roshal M. Multicolor Flow Cytometry and Multi-Gene Next Generation Sequencing Are Complimentary and Highly Predictive for Relapse in Acute Myeloid Leukemia Following Allogeneic Hematopoietic Stem Cell Transplant Blood. 128: 834-834. DOI: 10.1182/Blood.V128.22.834.834 |
0.42 |
|
| 2016 |
Boughan K, Dahi PB, Devlin S, Byam C, Yoo Y, Mazis C, Davis E, Nhaissi M, Paulson J, Wells D, Cooper C, Ponce DM, Giralt S, Papadopoulos EB, Kernan NA, et al. Despite Increasing Size of Unrelated Donor (URD) Registries and the Global Cord Blood (CB) Inventory Racial Disparities in Access to URD and CB Grafts Persist: A Prospective 10 Year Analysis of 1,112 Patients Blood. 128: 821-821. DOI: 10.1182/Blood.V128.22.821.821 |
0.465 |
|
| 2016 |
Hassoun H, Ruiz R, Kazunori M, Azzi K, Devlin S, Cooper B, Lendvai N, Landau H, Lesokhin AM, Chung DJ, Mailankody S, Korde NS, Giralt SA, Landgren O. Comparison of Standard Assays (Serum Immunofixation and Protein Electrophoresis) with Hevylite Assay in Patients with Multiple Myeloma Blood. 128: 5626-5626. DOI: 10.1182/Blood.V128.22.5626.5626 |
0.333 |
|
| 2016 |
Scordo M, Shah GL, Kosuri S, Herrera DA, Devlin S, Maloy MA, Nieves J, Borrill T, Avecilla ST, Meagher RC, O'Reilly RJ, Koehne G, Gyurkocza B, Castro-Malaspina H, Tamari R, et al. A Comprehensive Analysis of Late Toxicities and Associated Risk Factors in Long-Term Survivors of Myeloablative Conditioned Allogeneic Hematopoietic Cell Transplantation Using Ex-Vivo CD34+ Selection-Based Graft-Versus-Host Disease Prophylaxis Blood. 128: 4621-4621. DOI: 10.1182/Blood.V128.22.4621.4621 |
0.452 |
|
| 2016 |
Park JH, Devlin S, Lynch C, Schwartz A, Keegan T, Gonsalves L, Hermit K, Green M, Douer D, Tallman MS. Impact of Treatment Center Characteristics on Early Death Rates in Patients with Newly Diagnosed Acute Promyelocytic Leukemia: Analysis of Data from the SEER Program Blood. 128: 4008-4008. DOI: 10.1182/Blood.V128.22.4008.4008 |
0.356 |
|
| 2016 |
Coombs CC, Zehir A, Devlin S, Kishtagari A, Hyman DM, Solit D, Robson M, Baselga J, Arcila M, Tallman MS, Levine RL, Berger M. Mutational Analysis of Clonal Hematopoiesis in Solid Tumor Patients Illustrates the Critical Role of Systemic Anti-Cancer Therapies in the Evolution of Somatic Leukemia Disease Alleles Blood. 128: 37-37. DOI: 10.1182/Blood.V128.22.37.37 |
0.351 |
|
| 2016 |
Getta BM, Ghosh A, Coombs CC, Devlin S, Arcila M, Mohanty A, Levine RL, Tallman MS, Jakubowski AA, Giralt SA, Hanash AM. TP53 Mutations in AML Predict Adverse Outcome in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant Blood. 128: 3481-3481. DOI: 10.1182/Blood.V128.22.3481.3481 |
0.442 |
|
| 2016 |
Beyer K, Proli A, Zheng J, Devlin S, Bhatt V, Lin A, Papadopoulos EB, Jakubowski AA, Perales M, Giralt S, Castro-Malaspina H, Tamari R. Outcomes of Pharmacokinetically Targeted Busulfan-Based Conditioning Regimen for Patients with Myelodysplastic Syndrome and Acute Myelogenous Leukemia Undergoing CD34 Selected Allogeneic Hematopoietic Stem Cell Transplantation Blood. 128: 3392-3392. DOI: 10.1182/Blood.V128.22.3392.3392 |
0.453 |
|
| 2016 |
Getta B, Kishtagari A, Hilden P, Devlin S, Maloy MA, Gonzales PK, Shaffer BC, Ponce DM, Gyurkocza B, Barker JN, Papadopoulos EB, Castro-Malaspina H, Jakubowski AA, Young JW, Tallman MS, et al. Allogeneic Hematopoietic Stem Cell Transplantation Is Underutilized in Patients with Myelodysplastic Syndromes Blood. 128: 3188-3188. DOI: 10.1182/Blood.V128.22.3188.3188 |
0.506 |
|
| 2016 |
Lau C, Bhatt V, Dahi PB, Devlin S, Yoo Y, Adel NG, Mazis C, Perales M, Giralt SA, Koehne G, Ponce DM, Papanicolaou GA, Barker JN. Incidence, Severity, Day 100 Treatment Efficacy and Therapy Toxicity of Cytomegalovirus (CMV) Infections with Early Pre-Emptive Therapy in Adult Cord Blood (CB) Transplant Recipients Blood. 128: 2219-2219. DOI: 10.1182/Blood.V128.22.2219.2219 |
0.467 |
|
| 2016 |
Kosuri S, Herrera DA, Scordo M, Shah G, Maloy MA, Devlin S, Nieves J, Borrill T, Avecilla ST, Meagher RC, O'Reilly RJ, Koehne G, Shaffer BC, Gyurkocza B, Castro-Malaspina HR, et al. An Analysis of Early Toxicities, Associated Risk Factors and Survival during the First Year in Adults Undergoing Ex-Vivo CD34+ Selected Allogeneic Hematopoietic Cell Transplantation for Hematologic Malignancies Blood. 128: 2194-2194. DOI: 10.1182/Blood.V128.22.2194.2194 |
0.469 |
|
| 2016 |
Politikos I, Devlin S, Yoo Y, Mazis C, Maloy MA, Scaradavou A, Dahi PB, Perales M, Giralt S, Ponce DM, Barker JN. A Novel Intermediate Intensity Conditioning Regimen Achieves High Rates of Long-Term Outpatient Progression-Free Survival Offsetting the Disadvantage of Early Post-Transplant Complications in Adult Cord Blood (CB) Transplant Recipients Blood. 128: 2193-2193. DOI: 10.1182/Blood.V128.22.2193.2193 |
0.481 |
|
| 2016 |
Park JH, Ritchie EK, Rao AV, Devlin S, Hsu M, Khawaja TT, O'Donnell BA, Cazacu MI, Stopka DM, Tallman MS, Douer D. A Pediatric-Inspired Regimen Containing Multiple Doses of Intravenous Pegylated Asparaginase Appears Safe and Effective in Newly Diagnosed Adult Patients with Ph-Negative Acute Lymphoblastic Leukemia in Adults up to Age 60: Results of a Multi-Center Phase II Clinical Trial Blood. 128: 1629-1629. DOI: 10.1182/Blood.V128.22.1629.1629 |
0.357 |
|
| 2016 |
Shah GL, Scordo M, Kosuri S, Herrera DA, Maloy MA, Nieves J, Devlin S, Borrill T, Avecilla ST, Meagher RC, O'Reilly RJ, Koehne G, Shaffer BC, Perales M, Gyurkocza B, et al. Comparable Survival and Incidence of Toxicity for Older Adult Patients after CD34+ Selected Allogeneic Hematopoietic Stem Cell Transplantation Blood. 128: 1236-1236. DOI: 10.1182/Blood.V128.22.1236.1236 |
0.432 |
|
| 2016 |
Coombs C, Zehir A, Devlin S, Middha S, Cheng D, Kishtagari A, Hyman D, Solit D, Robson M, Baselga J, Arcila M, Tallman M, Levine R, Berger M. Abstract 2640: Clonal hematopoiesis identified by matched-normal blood sequencing of solid tumor patients without hematologic malignancy is common and is associated with decreased overall survival Epidemiology. 76: 2640-2640. DOI: 10.1158/1538-7445.Am2016-2640 |
0.347 |
|
| 2016 |
Barba P, Hilden P, Devlin SM, Maloy M, Ciolino C, Dierov D, Herman D, Mosesso K, Nieves J, Barker JN, Castro-Malaspina H, Jakubowski AA, Koehne G, Papadopoulos E, Sauter CS, et al. CD34+ Selected Ex-Vivo T-Cell Depleted (TCD) Grafts for Allogeneic Hematopoietic Cell Transplantation (Allo-HSCT) Is Associated with Low Incidence of Acute and Chronic Graft-Versus-Host Disease (GVHD) and High Chronic-Gvhd/Relapse-Free Survival Biology of Blood and Marrow Transplantation. 22. DOI: 10.1016/J.Bbmt.2015.11.909 |
0.457 |
|
| 2016 |
Kosuri S, Gyurkocza B, Devlin SM, Maloy M, Ciolino C, Borrill T, Jakubowski AA, Papadopoulos E, Castro-Malaspina H, Koehne G, Perales M, Giralt SA. Fractionated Infusion of Hematopoietic Progenitor Cells (HPC) Does Not Improve Neutrophil Recovery or Survival in Patients Undergoing Allogeneic Biology of Blood and Marrow Transplantation. 22. DOI: 10.1016/J.Bbmt.2015.11.900 |
0.441 |
|
| 2016 |
Proli AJ, Tamari R, Zheng J, Jakubowski AA, Papadopoulos E, Ponce DM, Devlin SM, Sauter CS, Perales M, Young JW, Giralt SA, Castro-Malaspina H. Impact of Busulfan Exposure on Transplant Outcomes for Patients with Advanced Myelodysplastic Syndrome Undergoing CD34 Selected Allogeneic Hematopoietic Stem Cell Transplantation Biology of Blood and Marrow Transplantation. 22. DOI: 10.1016/J.Bbmt.2015.11.841 |
0.478 |
|
| 2016 |
Bhatt V, Palazzo M, Kilroy K, Hilden P, Devlin SM, Maloy M, Barker JN, Castro-Malaspina H, Chung DJ, Dahi P, Hsu KC, Hanash AM, Jakubowski AA, Jenq R, Koehne G, et al. Low Dose Unfractionated Heparin (UFH) Prophylaxis Is a Feasible Strategy for the Prevention of Hepatic Sinusoidal Obstruction Syndrome (SOS) after Myeloablative Adult Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) Biology of Blood and Marrow Transplantation. 22. DOI: 10.1016/J.Bbmt.2015.11.740 |
0.415 |
|
| 2016 |
Gil-Cupello M, Shah GL, Maloy MA, Goldman DA, Devlin SM, Matasar MJ, Giralt SA, Sauter CS, Moskowitz CH, Perales M. Outcomes of Diffuse Large B-Cell Lymphoma (DLBCL) Patients Progressing after Autologous Hematopoietic Stem Cell Transplant Biology of Blood and Marrow Transplantation. 22. DOI: 10.1016/J.Bbmt.2015.11.641 |
0.447 |
|
| 2016 |
Cho C, Eaton A, Barker JN, Castro-Malaspina H, Devlin SM, Moskowitz A, Sauter CS, Moskowitz CH, Perales M. Functional Imaging Predicts Progression-Free Survival after Allogeneic Hematopoietic Stem Cell Transplantation (HCT) in Relapsed/Refractory Hodgkin Lymphoma Biology of Blood and Marrow Transplantation. 22. DOI: 10.1016/J.Bbmt.2015.11.619 |
0.448 |
|
| 2016 |
Assal A, Jakubowski AA, Maloy M, Zheng J, Devlin SM, Avecilla S, Barker JN, Castro-Malaspina H, Dahi P, Gyurkocza B, Meagher R, Perales M, Shaffer B, Tamari R, Young JW, et al. The Role of Post-Remission Chemotherapy before T-Cell Depleted Allogeneic Stem Cell Transplant for Acute Myeloid Leukemia in First Complete Remission Biology of Blood and Marrow Transplantation. 22: S197-S198. DOI: 10.1016/J.Bbmt.2015.11.587 |
0.463 |
|
| 2016 |
Cho C, Hsu M, Avecilla S, Barba P, Barker JN, Castro-Malaspina H, Devlin SM, Giralt SA, Jakubowski AA, Koehne G, Meagher R, O'Reilly RJ, Papadopoulos E, Ponce DM, van den Brink MR, et al. Long-Term Prognosis Among 1-Year Survivors of Ex Vivo T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation: A Landmark Analysis Biology of Blood and Marrow Transplantation. 22: S84-S85. DOI: 10.1016/J.Bbmt.2015.11.380 |
0.432 |
|
| 2016 |
Politikos I, Devlin SM, Yoo Y, Lauer E, Ciolino C, Dierov D, Herman D, Mosesso K, Nieves J, Giralt SA, Perales M, Kernan NA, Scaradavou A, Ponce DM, Barker JN. Double Unit Cord Blood Transplantation (dCBT) Progression-Free Survival (PFS) is Unaffected by Grade III-IV Acute Graft-Versus-Host Disease (aGVHD) and Survivors Are Likely to Discontinue Immunosuppression (IS) and Reconstitute T-Cells Biology of Blood and Marrow Transplantation. 22. DOI: 10.1016/J.Bbmt.2015.11.373 |
0.456 |
|
| 2016 |
Kosuri S, Hilden P, Devlin SM, Yoo Y, Lauer E, Peled JU, Avecilla S, Castro-Malaspina H, Dahi P, Giralt SA, Gyurkocza B, Jakubowski AA, Meagher R, Papadopoulos E, Perales M, et al. High Progression-Free Survival (PFS) in Adult Double Unit Cord Blood (dCB) Transplant Recipients with High Risk Disease after a Novel Intermediate Intensity Conditioning Regimen Biology of Blood and Marrow Transplantation. 22: S76-S77. DOI: 10.1016/J.Bbmt.2015.11.370 |
0.427 |
|
| 2016 |
Shah GL, Weltz J, Zhou Q, Devlin SM, Landau H, Chung DJ, Lendvai N, Lesokhin AM, Korde N, Koehne G, Giralt SA, Hassoun H. A Response Adapted Approach to Induction Treatment in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation Biology of Blood and Marrow Transplantation. 22. DOI: 10.1016/J.Bbmt.2015.11.321 |
0.46 |
|
| 2015 |
Barba P, Burns LJ, Litzow MR, Juckett MB, Komanduri KV, Lee SJ, Devlin SM, Costa LJ, Khan S, King A, Klein A, Krishnan A, Malone A, Mir M, Moravec C, et al. Success of an International Learning Healthcare System in Hematopoietic Cell Transplantation: the American Society of Blood and Marrow Transplantation Clinical Case Forum. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. PMID 26718665 DOI: 10.1016/J.Bbmt.2015.12.008 |
0.433 |
|
| 2015 |
Chung DJ, Pronschinske KB, Shyer JA, Sharma S, Leung S, Curran SA, Lesokhin AM, Devlin SM, Giralt SA, Young JW. T-cell Exhaustion in Multiple Myeloma Relapse after Autotransplant: Optimal Timing of Immunotherapy. Cancer Immunology Research. PMID 26464015 DOI: 10.1158/2326-6066.Cir-15-0055 |
0.424 |
|
| 2015 |
Jones LW, Devlin SM, Maloy MA, Wood WA, Tuohy S, Espiritu N, Aquino J, Kendig T, Michalski MG, Gyurkocza B, Schaffer WL, Ali B, Giralt S, Jakubowski AA. Prognostic Importance of Pretransplant Functional Capacity After Allogeneic Hematopoietic Cell Transplantation. The Oncologist. 20: 1290-7. PMID 26446235 DOI: 10.1634/Theoncologist.2015-0200 |
0.394 |
|
| 2015 |
Tiacci E, Park JH, De Carolis L, Chung SS, Broccoli A, Scott S, Zaja F, Devlin S, Pulsoni A, Chung YR, Cimminiello M, Kim E, Rossi D, Stone RM, Motta G, et al. Targeting Mutant BRAF in Relapsed or Refractory Hairy-Cell Leukemia. The New England Journal of Medicine. PMID 26352686 DOI: 10.1056/Nejmoa1506583 |
0.353 |
|
| 2015 |
Smith E, Devlin SM, Orlando E, Landau H, Lesokhin AM, Chung DJ, Hassoun H, Lendvai N, Landgren O, Giralt S, Chari A, Jagannath S, Koehne G. CD34-selected allogeneic hematopoietic stem cell transplantation for patients with relapsed, high-risk multiple myeloma. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. PMID 26325439 DOI: 10.1016/J.Bbmt.2015.08.025 |
0.493 |
|
| 2015 |
Shah GL, Shune L, Purtill D, Devlin S, Lauer E, Lubin M, Bhatt V, McElrath C, Kernan NA, Scaradavou A, Giralt S, Perales MA, Ponce DM, Young JW, Shah M, et al. Robust Vaccine Responses in Adult and Pediatric Cord Blood Transplantation Recipients Treated for Hematologic Malignancies. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. PMID 26271191 DOI: 10.1016/J.Bbmt.2015.08.010 |
0.327 |
|
| 2015 |
Ponce DM, Hilden P, Devlin SM, Maloy M, Lubin M, Castro-Malaspina H, Dahi P, Hsu K, Jakubowski AA, Kernan NA, Koehne G, O'Reilly RJ, Papadopoulos EB, Perales MA, Sauter C, et al. High Disease-Free Survival with Enhanced Protection against Relapse after Double-Unit Cord Blood Transplantation When Compared with T Cell-Depleted Unrelated Donor Transplantation in Patients with Acute Leukemia and Chronic Myelogenous Leukemia. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. PMID 26238810 DOI: 10.1016/J.Bbmt.2015.07.029 |
0.515 |
|
| 2015 |
Tamari R, Chung SS, Papadopoulos EB, Jakubowski AA, Hilden P, Devlin SM, Goldberg JD, Perales MA, Ponce DM, Sauter CS, Maloy MA, Herman DY, Klimek V, Young JW, O'Reilly RJ, et al. CD34-Selected Hematopoietic Stem Cell Transplants Conditioned with Myeloablative Regimens and Antithymocyte Globulin for Advanced Myelodysplastic Syndrome: Limited Graft-versus-Host Disease without Increased Relapse. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. PMID 26187863 DOI: 10.1016/J.Bbmt.2015.07.010 |
0.474 |
|
| 2015 |
Mussetti A, Devlin SM, Castro-Malaspina HR, Barker JN, Giralt SA, Zelenetz AD, Sauter CS, Perales MA. Non-myeloablative allogeneic hematopoietic stem cell transplantation for adults with relapsed and refractory mantle cell lymphoma: a single-center analysis in the rituximab era. Bone Marrow Transplantation. PMID 26146802 DOI: 10.1038/Bmt.2015.156 |
0.456 |
|
| 2015 |
Watts JM, Kishtagari A, Hsu M, Lacouture ME, Postow MA, Park JH, Stein EM, Teruya-Feldstein J, Abdel-Wahab O, Devlin SM, Tallman MS. Melanoma and non-melanoma skin cancers in hairy cell leukaemia: a Surveillance, Epidemiology and End Results population analysis and the 30-year experience at Memorial Sloan Kettering Cancer Center. British Journal of Haematology. PMID 26115047 DOI: 10.1111/Bjh.13528 |
0.32 |
|
| 2015 |
Jenq R, Taur Y, Devlin S, Ponce D, Goldberg J, Ahr KF, Littmann ER, Ling L, Gobourne AC, Miller LC, Docampo MD, Peled JU, Arpaia N, Cross J, Peets TK, et al. Intestinal Blautia Is Associated with Reduced Death from Graft-versus-Host Disease. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. PMID 25977230 DOI: 10.1016/J.Bbmt.2015.04.016 |
0.405 |
|
| 2015 |
Ganzel C, Devlin S, Douer D, Rowe JM, Stein EM, Tallman MS. Secondary acute lymphoblastic leukaemia is constitutional and probably not related to prior therapy. British Journal of Haematology. 170: 50-5. PMID 25823602 DOI: 10.1111/Bjh.13386 |
0.412 |
|
| 2015 |
Sauter CS, Matasar MJ, Meikle J, Schoder H, Ulaner GA, Migliacci JC, Hilden P, Devlin SM, Zelenetz AD, Moskowitz CH. Prognostic value of FDG-PET prior to autologous stem cell transplantation for relapsed and refractory diffuse large B-cell lymphoma. Blood. 125: 2579-81. PMID 25758829 DOI: 10.1182/Blood-2014-10-606939 |
0.438 |
|
| 2015 |
Harnicar S, Ponce DM, Hilden P, Zheng J, Devlin SM, Lubin M, Pozotrigo M, Mathew S, Adel N, Kernan NA, O'Reilly R, Prockop S, Scaradavou A, Hanash A, Jenq R, et al. Intensified Mycophenolate Mofetil Dosing and Higher Mycophenolic Acid Trough Levels Reduce Severe Acute Graft-versus-Host Disease after Double-Unit Cord Blood Transplantation. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. 21: 920-5. PMID 25687796 DOI: 10.1016/J.Bbmt.2015.01.024 |
0.452 |
|
| 2015 |
Hobbs GS, Hamdi A, Hilden PD, Goldberg JD, Poon ML, Ledesma C, Devlin SM, Rondon G, Papadopoulos EB, Jakubowski AA, O'Reilly RJ, Champlin RE, Giralt S, Perales MA, Kebriaei P. Comparison of outcomes at two institutions of patients with ALL receiving ex vivo T-cell-depleted or unmodified allografts. Bone Marrow Transplantation. 50: 493-8. PMID 25621808 DOI: 10.1038/Bmt.2014.302 |
0.426 |
|
| 2015 |
Ceberio I, Dai K, Devlin SM, Barker JN, Castro-Malaspina H, Goldberg JD, Giralt S, Adel NG, Perales MA. Safety of voriconazole and sirolimus coadministration after allogeneic hematopoietic SCT. Bone Marrow Transplantation. 50: 438-43. PMID 25599164 DOI: 10.1038/bmt.2014.286 |
0.307 |
|
| 2015 |
Singh Abbi KK, Zheng J, Devlin SM, Giralt S, Landau H. Second autologous stem cell transplant: an effective therapy for relapsed multiple myeloma. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. 21: 468-72. PMID 25529381 DOI: 10.1016/J.Bbmt.2014.11.677 |
0.484 |
|
| 2015 |
Ponce DM, Hilden P, Mumaw C, Devlin SM, Lubin M, Giralt S, Goldberg JD, Hanash A, Hsu K, Jenq R, Perales MA, Sauter C, van den Brink MR, Young JW, Brentjens R, et al. High day 28 ST2 levels predict for acute graft-versus-host disease and transplant-related mortality after cord blood transplantation. Blood. 125: 199-205. PMID 25377785 DOI: 10.1182/Blood-2014-06-584789 |
0.475 |
|
| 2015 |
Dahi PB, Perales MA, Devlin SM, Olson A, Lubin M, Gonzales AM, Scaradavou A, Kernan NA, O'Reilly RJ, Giralt S, Jakubowski A, Koehne G, Papadopoulos EB, Ponce DM, Sauter C, et al. Incidence, nature and mortality of cytomegalovirus infection after double-unit cord blood transplant. Leukemia & Lymphoma. 56: 1799-805. PMID 25224458 DOI: 10.3109/10428194.2014.963079 |
0.45 |
|
| 2015 |
Ceberio I, Devlin SM, Sauter C, Barker JN, Castro-Malaspina H, Giralt S, Ponce DM, Lechner L, Maloy MA, Goldberg JD, Perales MA. Sirolimus, tacrolimus and low-dose methotrexate based graft-versus-host disease prophylaxis after non-ablative or reduced intensity conditioning in related and unrelated donor allogeneic hematopoietic cell transplant. Leukemia & Lymphoma. 56: 663-70. PMID 24913499 DOI: 10.3109/10428194.2014.930851 |
0.509 |
|
| 2015 |
Ganzel C, Mathews V, Alimoghaddam K, Ghavamzadeh A, Kuk D, Devlin S, Wang H, Weisdorf D, Douer D, Rowe JM, Nagler A, Mohty M, Tallman MS, Estev J, Zhang M. Autologous Transplant, and Not ATO Alone, Remains the Preferred Therapy for Relapsed APL: A Report from the CIBMTR, EBMT and Two Specialized Centers Blood. 126: 928-928. DOI: 10.1182/Blood.V126.23.928.928 |
0.525 |
|
| 2015 |
Perales M, Cho C, Eaton A, Moskowitz AJ, Nguyen V, Gonzales-Dadiz AMR, Devlin S, Giralt SA, Jakubowski AA, Matasar MJ, Noy A, Portlock CS, Straus DJ, Young JW, Barker JN, et al. A Prospective Study of Allogeneic Hematopoietic Stem Cell Transplantation in Relapsed/ Refractory Hodgkin Lymphoma Blood. 126: 4383-4383. DOI: 10.1182/Blood.V126.23.4383.4383 |
0.483 |
|
| 2015 |
Land J, Afifi S, Adel NG, Devlin S, Arora A, Lendvai N, Landgren O. Incidence and Management of Proteasome Inhibitor-Related Cardiotoxicity in Multiple Myeloma Patients at Memorial Sloan Kettering Cancer Center Blood. 126: 4265-4265. DOI: 10.1182/Blood.V126.23.4265.4265 |
0.379 |
|
| 2015 |
Lendvai N, Devlin S, Patel M, Knapp KM, Ekman D, Grundberg I, Chung DJ, Hassoun H, Koehne G, Lesokhin AM, Landau H, Giralt SA, Korde NS, Landgren O. Biomarkers of Cardiotoxicity Among Multiple Myeloma Patients Subsequently Treated with Proteasome Inhibitor Therapy Blood. 126: 4257-4257. DOI: 10.1182/Blood.V126.23.4257.4257 |
0.338 |
|
| 2015 |
Reiss SN, Buie LW, Adel NG, Goldman DA, Devlin S, Douer D. Hypoalbuminemia Is Significantly Associated with Increased Clearance Time of High Doses of Methotrexate Blood. 126: 3711-3711. DOI: 10.1182/Blood.V126.23.3711.3711 |
0.398 |
|
| 2015 |
Kosuri S, Hilden P, Devlin S, Yoo Y, Lauer E, Peled J, Parastoo DB, Giralt SA, Gyurkocza B, Castro-Malaspina H, Jakubowski AA, Papadopoulos EB, Perales M, Sauter CS, Shaffer BC, et al. Age-Adjusted Co-Morbidity Score - but Not Revised Disease Risk Index - Is Associated with Progression-Free Survival after Intermediate Intensity Double Unit CBT in Adults with Hematologic Malignancies Blood. 126: 3231-3231. DOI: 10.1182/Blood.V126.23.3231.3231 |
0.493 |
|
| 2015 |
Kosuri S, Gyurkocza B, Devlin S, Maloy M, Ciolino C, Borrill T, Jakubowski AA, Papadopoulos EB, Castro-Malaspina HR, Koehne G, Perales M, Giralt S. Fractionated Infusion of Hematopoietic Progenitor Cells Does Not Improve Neutrophil Recovery or Survival in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Hematologic Malignancies Blood. 126: 3095-3095. DOI: 10.1182/Blood.V126.23.3095.3095 |
0.488 |
|
| 2015 |
Coombs CC, Devlin S, Dixit S, Mohanty A, Knapp KM, Arcila M, Klimek VM, Tallman MS, Levine RL, Rampal RK, Rapaport F. Response to Hypomethylating Agent Therapy in Acute Myeloid Leukemia Based upon Mutations in the DNA Methylation Pathway Blood. 126: 2522-2522. DOI: 10.1182/Blood.V126.23.2522.2522 |
0.374 |
|
| 2015 |
Coombs CC, Zehir A, Devlin S, Middha S, Cheng D, Kishtagari A, Hyman DM, Solit D, Robson M, Baselga J, Arcila M, Ladanyi M, Tallman MS, Levine RL, Berger M. Next-Generation Sequencing of Matched Normal Blood Identifies Clonal Hematopoiesis in a Significant Subset of Solid Tumor Patients without Hematologic Malignancies Blood. 126: 2447-2447. DOI: 10.1182/Blood.V126.23.2447.2447 |
0.385 |
|
| 2015 |
Soff AP, Dong J, Dong A, Devlin S, Mantha S, Parameswaran R, Soff GA. Reduced Emergency Room Utilization for Initiation of Anticoagulation with Rivaroxaban Versus Low Molecular Weight Heparin for Treatment of Cancer-Associated Thrombosis Blood. 126: 2068-2068. DOI: 10.1182/Blood.V126.23.2068.2068 |
0.336 |
|
| 2015 |
Shah GL, Hsu M, Devlin S, Chung DJ, Hassoun H, Koehne G, Korde NS, Lendvai N, Lesokhin AM, Landgren O, Landau H, Giralt SA. Autologous Hematopoietic Stem Cell Transplantation Overcomes Primary Refractory Disease in Multiple Myeloma Patients Treated with Novel Agents Blood. 126: 1996-1996. DOI: 10.1182/Blood.V126.23.1996.1996 |
0.477 |
|
| 2015 |
Chung DJ, Pronschinske KB, Shyer JA, Sharma S, Leung S, Curran SA, Lesokhin AM, Devlin S, Giralt SA, Young JW. T Cell Exhaustion/Senescence in Relapsed Multiple Myeloma after Autologous Stem Cell Transplantation Blood. 126: 1966-1966. DOI: 10.1182/Blood.V126.23.1966.1966 |
0.424 |
|
| 2015 |
Tamari R, Anthony P, Zheng J, Jakubowski AA, Papadopoulos EB, Ponce DM, Devlin S, Sauter CS, Young JW, Giralt SA, Castro-Malaspina HR. Impact of Busulphan Exposure on Transplant Outcomes for Patients with Advanced Myelodysplastic Syndromes Undergoing CD34 Selected Allogeneic Hematopoietic Cell Transplantation Blood. 126: 1911-1911. DOI: 10.1182/Blood.V126.23.1911.1911 |
0.47 |
|
| 2015 |
Billel G, Smith EL, Dogan A, Hsu M, Devlin S, Pichardo JD, Chung DJ, Koehne G, Korde NS, Landau HJ, Giralt SA, Landgren O, Hassoun H, Lesokhin AM. Presence of PD-1 Expressing T Cells Predicts for Inferior Overall Survival in Newly Diagnosed Multiple Myeloma Blood. 126: 1785-1785. DOI: 10.1182/Blood.V126.23.1785.1785 |
0.332 |
|
| 2015 |
Getta B, Woo KM, Devlin S, Park JH, Abdel-Wahab O, Tallman MS. Hairy Cell Leukemia Variant Has Similar Survival to Classical Disease Despite Poorer Responses to Initial Therapy: A 30-Year Experience from Memorial Sloan Kettering Cancer Center Blood. 126: 1476-1476. DOI: 10.1182/Blood.V126.23.1476.1476 |
0.396 |
|
| 2015 |
Peterson TJ, Lin A, Hilden P, Devlin S, Adel NG, Park JH. Effects of Obesity on the Efficacy and Toxicity of Induction Chemotherapy in Adult Acute Lymphoblastic Leukemia (ALL) Blood. 126: 1290-1290. DOI: 10.1182/Blood.V126.23.1290.1290 |
0.329 |
|
| 2015 |
Coombs CC, Kuk D, Devlin S, Siegelbaum R, Parameswaran R, Mantha S, Soff GA. Outcomes of Inferior Vena Cava Filter Placement in a Large Population of Cancer Patients Diagnosed with Pulmonary Embolism: Risk for Recurrent Venous Thromboembolism, Survival, and Filter-Related Complications Blood. 126: 1112-1112. DOI: 10.1182/Blood.V126.23.1112.1112 |
0.372 |
|
| 2015 |
Sanchez M, Abbi K, Tamari R, Jakubowski A, Papadopoulos E, Devlin S, Sauter C, Barker JN, Boulad F, Giralt S, Meagher R, Castro-Malaspina H. 86 Allogeneic Transplantation For Chronic Myelomonocytic Leukemia (Cmml) Is Associated With High Disease-Free Survival Even In The Setting Of High-Risk Disease Leukemia Research. 39. DOI: 10.1016/S0145-2126(15)30087-4 |
0.407 |
|
| 2015 |
Tamari R, Oran B, Hilden P, Papadopoulos E, Kongtim P, Rondon G, Jakubowski A, Anderssson B, Devlin S, Ahmed S, Young J, Popat U, Chen J, De Lima M, O'Reilly R, et al. 16 OUTCOMES IN PATIENTS WITH ADVANCED MYELODYSPLASTIC SYNDROME RECEIVING EX-VIVO T-CELL DEPLETED OR UNMODIFIED ALLOGRAFTS: COMPARISON OF RESULTS AT TWO INSTITUTIONS Leukemia Research. 39: S6-S7. DOI: 10.1016/S0145-2126(15)30017-5 |
0.379 |
|
| 2015 |
Koehne G, Devlin S, Landau H, Hassoun H, Lesokhin A, Lendvai N, Chung D, Giralt S. CD34-selected allogeneic hematopoietic stem cell transplantation for patients with relapsed, high-risk multiple myeloma Clinical Lymphoma Myeloma and Leukemia. 15: e280. DOI: 10.1016/J.CLML.2015.07.577 |
0.377 |
|
| 2015 |
Shah GL, Weltz J, Zhou Q, Devlin SM, Landau H, Chung DJ, Lendvai N, Lesokhin AM, Korde N, Koehne G, Giralt SA, Hassoun H. A Response Adapted Approach to Induction Treatment Yields acceptable Outcome in Patients with Multiple Myeloma (MM) undergoing Autologous Stem Cell transplantation (ASCT) Clinical Lymphoma, Myeloma & Leukemia. 15. DOI: 10.1016/J.Clml.2015.07.357 |
0.419 |
|
| 2015 |
Ponce DM, Devlin S, Bhatt V, Pozotrigo M, Lubin M, Lauer E, Kernan NA, Scaradavou A, Hanash AM, Perales M, Brink MRMvd, Young JW, Giralt S, Barker J. In Landmark Analysis the Severity of Day 100 Acute Graft-Versus-Host Disease (aGVHD) Has No Impact on Long-Term Progression-Free Survival (PFS) after Double-Unit Cord Blood Transplantation (DCBT) Biology of Blood and Marrow Transplantation. 21. DOI: 10.1016/J.Bbmt.2014.11.551 |
0.425 |
|
| 2015 |
Bhatt V, Shune L, Lauer E, Lubin M, Devlin S, Scaradavou A, Kernan NA, Giralt S, Parameswaran R, Perales M, Ponce DM, Soff GA, Barker J. Autoimmune Hemolysis (AH) & Immune Thrombocytopenic Purpura (ITP) after Cord Blood Transplantation (CBT) May be Life-Threatening & Warrant Early Therapy with Rituximab Biology of Blood and Marrow Transplantation. 21. DOI: 10.1016/J.Bbmt.2014.11.380 |
0.357 |
|
| 2015 |
Shah GL, Landry C, Londono D, Devlin S, Kosuri S, Lesokhin AM, Lendvai N, Hassoun H, Chung DJ, Koehne G, Jhanwar S, Landgren O, Landau H, Giralt S. Gain of Chromosome 1q Portends Worse Prognosis in Multiple Myeloma Patients Treated with Novel Agent Based Induction Regimens Even after Autologous Transplantation Biology of Blood and Marrow Transplantation. 21. DOI: 10.1016/J.Bbmt.2014.11.311 |
0.402 |
|
| 2015 |
Dahi P, Ponce DM, Byam C, Devlin S, Lubin M, Lauer E, Sideroff M, Wells D, Papadopoulos E, Giralt S, Young JW, Kernan NA, Scaradavou A, Barker J. Extension of Minority Transplant Access Using Domestic Units Supports the Importance of Public CB Bank Funding: An 884 Patient Analysis Biology of Blood and Marrow Transplantation. 21. DOI: 10.1016/J.Bbmt.2014.11.225 |
0.42 |
|
| 2015 |
Dahi PB, Sauter CS, Devlin SM, Lubin MN, Ponce DM, Giralt S, Koehne G, Perales M, Zelenetz AD, Moskowitz CH, Barker JN. Successful Salvage of High-Risk B-Cell Non-Hodgkin and Hodgkin Lymphoma (NHL/HL) with Double-Unit Cord Blood Transplantation (DCBT) Provides a Platform for Further Optimization Biology of Blood and Marrow Transplantation. 21. DOI: 10.1016/J.Bbmt.2014.11.101 |
0.406 |
|
| 2015 |
Jones LW, Devlin S, Malroy M, Espiritu N, Aquino J, Hall C, Wood WA, Michalski M, Gyurkocza B, Giralt S, Jakubowski AA. Prognostic Importance of Functional Capacity for Pre-Transplant Risk Assessment Among Patients Undergoing Allogeneic Hematopoietic Cell Transplantation Biology of Blood and Marrow Transplantation. 21. DOI: 10.1016/J.Bbmt.2014.11.026 |
0.482 |
|
| 2014 |
Purtill D, Smith K, Devlin S, Meagher R, Tonon J, Lubin M, Ponce DM, Giralt S, Kernan NA, Scaradavou A, Stevens CE, Barker JN. Dominant unit CD34+ cell dose predicts engraftment after double-unit cord blood transplantation and is influenced by bank practice. Blood. 124: 2905-12. PMID 25185264 DOI: 10.1182/Blood-2014-03-566216 |
0.369 |
|
| 2014 |
Dahi PB, Tamari R, Devlin SM, Maloy M, Bhatt V, Scordo M, Goldberg J, Zelenetz AD, Hamlin PA, Matasar MJ, Maragulia J, Giralt SA, Perales MA, Moskowitz CH, Sauter CS. Favorable outcomes in elderly patients undergoing high-dose therapy and autologous stem cell transplantation for non-Hodgkin lymphoma. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. 20: 2004-9. PMID 25175794 DOI: 10.1016/J.Bbmt.2014.08.019 |
0.514 |
|
| 2014 |
Dahi PB, Ponce DM, Devlin S, Evans KL, Lubin M, Gonzales AM, Byam C, Sideroff M, Wells D, Giralt S, Kernan NA, Scaradavou A, Barker JN. Donor-recipient allele-level HLA matching of unrelated cord blood units reveals high degrees of mismatch and alters graft selection. Bone Marrow Transplantation. 49: 1184-6. PMID 25000459 DOI: 10.1038/Bmt.2014.135 |
0.343 |
|
| 2014 |
Lendvai N, Hilden P, Devlin S, Landau H, Hassoun H, Lesokhin AM, Tsakos I, Redling K, Koehne G, Chung DJ, Schaffer WL, Giralt SA. A phase 2 single-center study of carfilzomib 56 mg/m2 with or without low-dose dexamethasone in relapsed multiple myeloma. Blood. 124: 899-906. PMID 24963043 DOI: 10.1182/Blood-2014-02-556308 |
0.38 |
|
| 2014 |
Olson AL, Dahi PB, Zheng J, Devlin SM, Lubin M, Gonzales AM, Giralt SA, Perales MA, Papadopoulos EB, Ponce DM, Young JW, Kernan NA, Scaradavou A, O'Reilly RJ, Small TN, et al. Frequent human herpesvirus-6 viremia but low incidence of encephalitis in double-unit cord blood recipients transplanted without antithymocyte globulin. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. 20: 787-93. PMID 24548875 DOI: 10.1016/J.Bbmt.2014.02.010 |
0.507 |
|
| 2014 |
Sauter CS, Lechner L, Scordo M, Zheng J, Devlin SM, Fleming SE, Castro-Malaspina H, Moskowitz CH. Pretransplantation fluorine-18-deoxyglucose--positron emission tomography scan lacks prognostic value in chemosensitive B cell non-hodgkin lymphoma patients undergoing nonmyeloablative allogeneic stem cell transplantation. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. 20: 881-4. PMID 24534109 DOI: 10.1016/J.Bbmt.2014.02.009 |
0.383 |
|
| 2014 |
Dahi PB, Barone J, Devlin SM, Byam C, Lubin M, Ponce DM, Giralt S, Kernan NA, Scaradavou A, Hsu SH, Barker JN. Sustained donor engraftment in recipients of double-unit cord blood transplantation is possible despite donor-specific human leukoctye antigen antibodies. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. 20: 735-9. PMID 24462980 DOI: 10.1016/J.Bbmt.2014.01.017 |
0.453 |
|
| 2014 |
Parameswaran R, Lunning M, Mantha S, Devlin S, Hamilton A, Schwartz G, Soff G. Romiplostim for management of chemotherapy-induced thrombocytopenia. Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer. 22: 1217-22. PMID 24414994 DOI: 10.1007/S00520-013-2074-2 |
0.303 |
|
| 2014 |
Dahi PB, Ponce DM, Devlin S, Evans KL, Lubin MN, Gonzales AM, Tonon J, Meagher R, Giralt S, Kernan NA, Scaradavou A, Barker JN. "No wash" albumin-dextran dilution for double-unit cord blood transplantation is safe with high rates of sustained donor engraftment. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. 20: 490-4. PMID 24361912 DOI: 10.1016/J.Bbmt.2013.12.561 |
0.465 |
|
| 2014 |
Sauter CS, Barker JN, Lechner L, Zheng J, Devlin SM, Papadopoulos EB, Perales MA, Jakubowski AA, Goldberg JD, Koehne G, Ceberio I, Giralt S, Zelenetz AD, Moskowitz CH, Castro-Malaspina H. A phase II study of a nonmyeloablative allogeneic stem cell transplant with peritransplant rituximab in patients with B cell lymphoid malignancies: favorably durable event-free survival in chemosensitive patients. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. 20: 354-60. PMID 24315843 DOI: 10.1016/J.Bbmt.2013.11.029 |
0.52 |
|
| 2014 |
Landry CA, Londono D, Devlin S, Jhanwar S, Giralt S, Landau HJ. Multiple copies of MLL as a commonly detected cytogenetic abnormality in newly diagnosed symptomatic multiple myeloma. Journal of Clinical Oncology. 32. DOI: 10.1200/Jco.2014.32.15_Suppl.E19585 |
0.362 |
|
| 2014 |
Feller FM, Patel M, Devlin SM, Maloy M, Tallman MS, Perales M, Rampal RK. The Addition of Radiation Therapy to Initial Treatment for Extramedullary Acute Myeloid Leukemia Does Not Offer a Survival Benefit When Added to Chemotherapy Blood. 124: 960-960. DOI: 10.1182/Blood.V124.21.960.960 |
0.486 |
|
| 2014 |
Weltz JI, Landau H, Lendvai N, Chung DJ, Lesokhin AM, Devlin SM, Riedel E, Woo KM, Stellman A, Chimento D, Kewalramani T, Landgren O, Giralt S, Comenzo RL, Hassoun H. Interim Analysis of a Randomized Phase II Trial Comparing Continuous Lenalidomide and Dexamethasone to Autologous Stem Cell Transplantation in Multiple Myeloma Patients Responsive to Lenalidomide and Dexamethasone Induction Blood. 124: 3991-3991. DOI: 10.1182/Blood.V124.21.3991.3991 |
0.453 |
|
| 2014 |
Ogunniyi A, Rodriguez M, Devlin SM, Adel NG, Landau H, Chung DJ, Lendvai N, Lesokhin AM, Landgren O, Giralt SA, Hassoun H. Efficacy and Risk Factors Analysis of Upfront Autologous Stem Cell Mobilization Using Plerixafor and Granulocyte-Colony Stimulating Factor (GCSF) in Patients with Multiple Myeloma Blood. 124: 3856-3856. DOI: 10.1182/Blood.V124.21.3856.3856 |
0.428 |
|
| 2014 |
Ganzel C, Devlin SM, Douer D, Stein EM, Rowe JM, Tallman MS. Secondary ALL May be Independent of Prior Cytotoxic Therapy Blood. 124: 3648-3648. DOI: 10.1182/Blood.V124.21.3648.3648 |
0.432 |
|
| 2014 |
Beyer K, Rosner S, Woo KM, Devlin SM, Landau H, Hassoun H, Lendvai N, Chung DJ, Adel NG, Puto M, Landgren O, Giralt S, Lesokhin AM. Analysis of VDT-PACE Utilization in Multiple Myeloma Patients Treated at MSKCC for Relapsed Disease or Cytoreduction and Stem Cell Mobilization after Initial Induction Therapy Blood. 124: 3459-3459. DOI: 10.1182/Blood.V124.21.3459.3459 |
0.502 |
|
| 2014 |
Ponce DM, Hilden P, Devlin SM, Maloy M, Lubin MN, Castro-Malaspina H, Goldberg JD, Jakubowski AA, Meagher R, Papadopoulos EB, Perales M, Sauter CS, van den Brink MR, Young JW, Kernan NA, et al. Disease-Free Survival in Adult Patients with Acute Leukemia and Advanced CML Supports Use of Double-Unit Cord Blood Grafts As an Immediate Alternative to 8/8 HLA-Matched Unrelated Donors (URD) Blood. 124: 2588-2588. DOI: 10.1182/Blood.V124.21.2588.2588 |
0.415 |
|
| 2014 |
Sanchez ME, Abbi KKS, Tamari R, Jakubowsky A, Papadopoulos EB, Devlin SM, Shi W, Sauter CS, Barker JN, Boulad F, Giralt S, Meagher R, Castro-Malaspina H. Allogeneic Transplantation for Chronic Myelomonocytic Leukemia (CMML) Is Associated with High Disease-Free Survival Even in the Setting of High-Risk Disease Blood. 124: 2575-2575. DOI: 10.1182/Blood.V124.21.2575.2575 |
0.494 |
|
| 2014 |
Tamari R, Oran B, Hilden P, Papadopoulos EB, Kongtim P, Rondon G, Jakubowski AA, Andersson BS, Devlin SM, Ahmed S, Young JW, Popat UR, Chen J, Lima Md, O'Reilly RJ, et al. Allo- HSCT for Advanced Myelodysplastic Syndrome:MSKCC Vs MDACC Blood. 124: 2546-2546. DOI: 10.1182/Blood.V124.21.2546.2546 |
0.506 |
|
| 2014 |
Landry CA, Smith M, Chou JF, Devlin SM, Hassoun H, Bello C, Landgren O, Giralt S, Comenzo RL, Landau H. Increased Bone Marrow Plasma Cells at Diagnosis Predicts Overall Mortality in AL Amyloidosis Patients Undergoing Risk-Adapted Stem Cell Transplant Blood. 124: 2522-2522. DOI: 10.1182/Blood.V124.21.2522.2522 |
0.437 |
|
| 2014 |
Watts JM, Dumitriu B, Hilden P, Chen C, Rapaport F, Kishtagari A, Ahn J, Devlin SM, Rampal RK, Levine RL, Young NS, Tallman MS. Telomere Length Is Associated with Specific Mutations and Mutation Classes in Patients with Acute Myeloid Leukemia Blood. 124: 2280-2280. DOI: 10.1182/Blood.V124.21.2280.2280 |
0.369 |
|
| 2014 |
Dahi PB, Sauter CS, Devlin SM, Lubin MN, Ponce DM, Giralt S, Koehne G, Perales M, Zelenetz AD, Moskowitz CH, Barker JN. Successful Salvage of High-Risk B-Cell Non-Hodgkin and Hodgkin Lymphoma with Double-Unit Cord Blood Transplantation Provides a Platform for Further Optimization Blood. 124: 1258-1258. DOI: 10.1182/Blood.V124.21.1258.1258 |
0.55 |
|
| 2014 |
Purtill D, Ponce DM, Devlin SM, Lubin MN, Dahi PB, Giralt SA, Perales M, O'Reilly RJ, van den Brink MR, Young JW, Scaradavou A, Stevens C, Barker JN. Day 45 Lymphocyte Recovery Is Independently Associated with Transplant-Related Mortality after Adult Myeloablative Double-Unit Cord Blood Transplantation (dCBT) Blood. 124: 1156-1156. DOI: 10.1182/Blood.V124.21.1156.1156 |
0.429 |
|
| 2014 |
Bhatt V, Shune L, Lauer EJ, Lubin MN, Devlin SM, Scaradavou A, Kernan NA, Giralt S, Parameswaran R, Perales M, Ponce DM, Soff GA, Barker JN. Autoimmune Hemolysis & Immune Thrombocytopenic Purpura after Cord Blood Transplantation (CBT) May be Life-Threatening & Warrants Early Therapy with Rituximab Blood. 124: 1142-1142. DOI: 10.1182/Blood.V124.21.1142.1142 |
0.481 |
|
| 2014 |
Chung SS, Devlin S, Park CY. CD99 Identifies Disease Stem Cells in Acute Myeloid Leukemia (AML) and the Myelodysplastic Syndromes (MDS) Clinical Lymphoma Myeloma and Leukemia. 14: S121. DOI: 10.1016/J.Clml.2014.06.041 |
0.356 |
|
| 2014 |
Ponce DM, Harnicar S, Hilden P, Devlin S, Evans K, Lubin M, Kernan N, Prockop SE, Scaradavou A, Giralt SA, Goldberg JD, Perales M, Barker JN. Intensified Mycophenolate Mofetil (MMF) Dosing Is Safe from the Standpoint of Engraftment and Reduces Severe Acute Graft-Versus-Host Disease (aGVHD) after Double-Unit Cord Blood Transplantation (DCBT): An Analysis of 173 Patients Biology of Blood and Marrow Transplantation. 20. DOI: 10.1016/J.Bbmt.2013.12.469 |
0.445 |
|
| 2014 |
Ponce DM, Hilden P, Mumaw C, Devlin S, Lubin M, Evans K, Prockop SE, Scaradavou A, Kernan N, Giralt SA, Hsu K, Brink MRMvd, Young JW, Paczesny S, Barker JN. High Day 28 ST2 Biomarker Levels Predict Severe Day 100 Acute Graft-Versus-Host Disease and Day 180 Transplant-Related Mortality after Double-Unit Cord Blood Transplantation Biology of Blood and Marrow Transplantation. 20. DOI: 10.1016/J.Bbmt.2013.12.468 |
0.411 |
|
| 2014 |
Hobbs G, Kaur N, Ponce DM, Hilden P, Castro-Malaspina H, Giralt SA, Goldberg JD, Papadopoulos E, Jakubowski AA, Sauter CS, Koehne G, Devlin S, Barker JN, Perales M. A Novel Reduced Intensity Conditioning Regimen for Patients with High Risk Hematologic Malignancies Undergoing Conventional Allogeneic Stem Cell Transplantation Biology of Blood and Marrow Transplantation. 20. DOI: 10.1016/J.Bbmt.2013.12.390 |
0.48 |
|
| 2014 |
Wu S, Papadopoulos E, Maloy M, Hilden P, Devlin S, Barker J, Castro-Malaspina H, Goldberg JD, Koehne G, Perales M, Ponce DM, Sauter C, van den Brink MR, Young JW, Giralt SA, et al. Comparative Analysis of T CELL Depleted Matched Vs Mismatched Unrelated DONOR Transplants in Patients with Hematologic Malignancies Biology of Blood and Marrow Transplantation. 20: S142-S144. DOI: 10.1016/J.Bbmt.2013.12.220 |
0.487 |
|
| 2014 |
Dahi P, Ponce DM, Byam C, Devlin S, Lubin M, Evans K, Gonzales AM, Sideroff M, Wells D, Papadopoulos E, Giralt SA, Young JW, Kernan N, Scaradavou A, Barker JN. Prospective Evaluation of Alternative Donor Availability in 708 Patients: Improved Allograft Access with Enlarging Cord Blood (CB) Inventory for All Patients Including Racial and Ethnic Minorities Biology of Blood and Marrow Transplantation. 20. DOI: 10.1016/J.Bbmt.2013.12.213 |
0.391 |
|
| 2014 |
Barker JN, Ponce DM, Dahi P, Devlin S, Evans K, Lubin M, Meagher R, Castro-Malaspina H, Goldberg JD, Jakubowski AA, Koehne G, Papadopoulos E, Perales M, Sauter C, Kernan N, et al. Double-Unit Cord Blood (CB) Transplantation Combined with Haplo-Identical CD34+ Cells Results in 100% CB Engraftment with Enhanced Myeloid Recovery Biology of Blood and Marrow Transplantation. 20: 138-139. DOI: 10.1016/J.Bbmt.2013.12.212 |
0.407 |
|
| 2014 |
Mussetti A, Devlin S, Castro-Malaspina H, Barker JN, Giralt SA, Sauter C, Perales M. Reduced Intensity Conditioning Allogeneic Stem Cell Transplantation for Adults with Relapsed and Refractory Mantle Cell Lymphoma: A Single Center Retrospective Analysis in the Rituximab Era Biology of Blood and Marrow Transplantation. 20. DOI: 10.1016/J.Bbmt.2013.12.091 |
0.45 |
|
| 2014 |
Hobbs G, Kishtagari A, Hilden P, Barker JN, Jakubowski AA, Papadopoulos E, Devlin S, Boulad F, Kernan N, Kobos R, Steinherz PG, O'Reilly R, Giralt SA, Tallman M, Stein E, et al. Do Patients with High Risk or Relapsed Core Binding Factor Acute Myeloid Leukemia Benefit from Salvage Allogeneic Stem Cell Transplantation Biology of Blood and Marrow Transplantation. 20. DOI: 10.1016/J.Bbmt.2013.12.082 |
0.468 |
|
| 2014 |
Ponce DM, Devlin S, Lubin M, Maloy M, Castro-Malaspina H, Goldberg JD, Jakubowski AA, Papadopoulos E, Perales M, Sauter C, van den Brink MR, Young JW, Kernan N, O'Reilly R, Scaradavou A, et al. High Disease-Free Survival and Enhanced Protection Against Relapse after Double-Unit Cord Blood Transplantation (DCB-T) When Compared to Unrelated Donor Transplantation (URD-T) in Patients with Acute Leukemia, MDS and CML Biology of Blood and Marrow Transplantation. 20: S58-S59. DOI: 10.1016/J.Bbmt.2013.12.065 |
0.473 |
|
| 2014 |
Harnicar S, Ponce DM, Mathew S, Evans K, Zheng J, Devlin S, Pozotrigo M, Scaradavou A, Kernan NA, Adel NG, Barker JN. Higher Mycophenolic Acid (MPA) Trough Levels Result in Lower Day 100 Severe Acute Graft-Versus-Host Disease (aGVHD) without Increased Toxicity in Double-Unit Cord Blood Transplantation (CBT) Recipients Biology of Blood and Marrow Transplantation. 20. DOI: 10.1016/J.Bbmt.2013.12.054 |
0.419 |
|
| 2014 |
Tamari R, Devlin S, Goldberg JD, Hilden P, Jakubowski AA, Papadopoulos E, Ponce DM, Sauter C, Young J, Giralt SA, Castro-Malaspina H. Infections Are the Major Cause of Non Relapse Mortality (NRM) after T Cell Depleted (TCD) Allogeneic Hematopoietic Stem Cell Transplantation for Advanced Myelodysplastic Syndrome Biology of Blood and Marrow Transplantation. 20. DOI: 10.1016/J.Bbmt.2013.12.038 |
0.426 |
|
| 2014 |
Koehne G, Devlin S, Landau H, Hassoun H, Lesokhin AM, Lendvai N, Chung DJ, Bravo C, Giralt SA. T-Cell Depleted Allogeneic HSCT for Patients with Relapsed, High-Risk Multiple Myeloma Permits Long-Lasting Remissions in the Absence of Graft-Versus-Host Disease and Provides a Platform for Adoptive Immunotherapeutic Approaches Biology of Blood and Marrow Transplantation. 20: S38. DOI: 10.1016/J.Bbmt.2013.12.028 |
0.437 |
|
| 2013 |
Zamarin D, Devlin SM, Arcila ME, Landau H, Lesokhin A, Lendvai N, Chung DJ, Chimento D, Weltz J, Babu D, Giralt S, Hassoun H. Polyclonal immune activation and marrow plasmacytosis in multiple myeloma patients receiving long-term lenalidomide therapy: incidence and prognostic significance. Leukemia. 27: 2422-4. PMID 23608883 DOI: 10.1038/Leu.2013.126 |
0.345 |
|
| 2013 |
Ponce DM, Sauter C, Devlin S, Lubin M, Gonzales AM, Kernan NA, Scaradavou A, Giralt S, Goldberg JD, Koehne G, Perales MA, Young JW, Castro-Malaspina H, Jakubowski A, Papadopoulos EB, et al. A novel reduced-intensity conditioning regimen induces a high incidence of sustained donor-derived neutrophil and platelet engraftment after double-unit cord blood transplantation. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. 19: 799-803. PMID 23416850 DOI: 10.1016/J.Bbmt.2013.02.007 |
0.49 |
|
| 2013 |
Zamarin D, Giralt S, Landau H, Lendvai N, Lesokhin A, Chung D, Koehne G, Chimento D, Devlin SM, Riedel E, Bhutani M, Babu D, Hassoun H. Patterns of relapse and progression in multiple myeloma patients after auto-SCT: implications for patients' monitoring after transplantation. Bone Marrow Transplantation. 48: 419-24. PMID 22890289 DOI: 10.1038/Bmt.2012.151 |
0.312 |
|
| 2013 |
Watts JM, Kishtagari A, Devlin S, Stein EM, Park JH, Lacouture ME, Tallman M. Increased Incidence Of Melanoma and Non-Melanoma Skin Cancers In Patients With Hairy Cell Leukemia: A Single Institution Experience With 267 Patients From Memorial Sloan-Kettering Cancer Center Blood. 122: 5274-5274. DOI: 10.1182/Blood.V122.21.5274.5274 |
0.354 |
|
| 2013 |
Smith KM, Kuk D, Devlin SM, Maslak PG, Giralt S, Koehne G. Multiparameter Flow Cytometry For Detection Of Minimal Residual Disease In Multiple Myeloma After T-Cell Depleted Allogeneic Stem Cell Transplant Blood. 122: 4647-4647. DOI: 10.1182/Blood.V122.21.4647.4647 |
0.4 |
|
| 2013 |
Ponce DM, Harnicar SJ, Devlin S, Hilden P, Evans KL, Lubin MN, Giralt SA, Goldberg JD, Perales M, Kernan NA, Prockop SE, Scaradavou A, Barker JN. Intensified Mycophenolate Mofetil (MMF) Dosing Every 8 Hours Is Safe From The Standpoint Of Engraftment and May Ameliorate Severe Acute Graft-Versus-Host Disease (GVHD) After Double-Unit Cord Blood Transplantation (CBT) Blood. 122: 4600-4600. DOI: 10.1182/Blood.V122.21.4600.4600 |
0.479 |
|
| 2013 |
Rampal RK, Devlin SM, Mckenney AS, Knapp KM, Patel M, Wang K, Nahas MK, Yelensky R, Otto GA, Lipson D, Stephens PJ, Miller VA, Manshouri T, Verstovsek S, Levine RL. High-Throughput Mutational Profiling Of Post-Myeloproliferative Neoplasm Acute Myeloid Leukemia Reveals Frequent Mutations In NRAS In JAK2V617F-Negative Post-MPN AML Blood. 122: 4098-4098. DOI: 10.1182/Blood.V122.21.4098.4098 |
0.32 |
|
| 2013 |
Ceberio I, Hilden P, Devlin SM, Maloy M, Goldberg JD, Perales MA, Barker JN, Castro-Malaspina H, Koehne G, Ponce DM, Sauter CS, van den Brink MR, Young JW, O'Reilly RJ, Giralt S, et al. T-Cell Depleted (TCD) Hematopoietic Stem Cell Transplantation (HCT) For Adult Patients With Acute Myelogenous Leukemia (AML) In First and Second Remission: Long-Term Disease Free Survival(DFS) With a Significantly Reduced Risk Of Graft-Versus-Host Disease(GvHD) Blood. 122: 3387-3387. DOI: 10.1182/Blood.V122.21.3387.3387 |
0.462 |
|
| 2013 |
Tamari R, Jakubowski AA, Papadopoulos EB, Giralt SA, Goldberg JD, Ponce DM, Sauter CS, Hilden P, Devlin S, Young JW, Castro-Malaspina H. Adverse Cytogenetic Abnormalities At Diagnosis Are The Most Important Predictor Of Relapse Post T Cell Depleted (TCD) Allogeneic Hematopoietic Stem Cell Transplantation In Patients With Advanced Myelodysplastic Syndrome (MDS) Blood. 122: 3379-3379. DOI: 10.1182/Blood.V122.21.3379.3379 |
0.522 |
|
| 2013 |
Soriano Hobbs G, Hilden P, Hamdi A, Goldberg JD, Poon M, Ledesma C, Devlin S, Rondon G, Papadopoulos EB, Jakubowski AA, O'Reilly RJ, Champlin RE, Giralt SA, Kebriaei P, Perales MA. Outcomes In Patients With Acute Lymphoblastic Leukemia In First Or Second Complete Remission Receiving Ex-Vivo T-Cell Depleted Or Unmodified Allografts: Comparison Of Results At Two Institutions Blood. 122: 3370-3370. DOI: 10.1182/Blood.V122.21.3370.3370 |
0.51 |
|
| 2013 |
Ponce DM, Gregornik D, Mathew S, Evans KL, Zheng J, Devlin S, Pozotrigo M, Scaradavou A, Kernan NA, Adel NG, Barker JN. Higher Mycophenolic Acid (MPA) Trough Levels Result In Lower Day 100 Severe Acute GVHD Without Increased Toxicity In Double-Unit Cord Blood Transplantation (CBT) Recipients Blood. 122: 3297-3297. DOI: 10.1182/Blood.V122.21.3297.3297 |
0.493 |
|
| 2013 |
Barker JN, Ponce DM, Dahi PB, Devlin S, Evans KL, Lubin MN, Meagher R, Reich L, Castro-Malaspina H, Goldberg JD, Jakubowski AA, Koehne G, Papadopoulos EB, Perales M, Sauter CS, et al. Double-Unit Cord Blood (CB) Transplantation Combined With Haplo-Identical CD34+ Cell-Selected PBSC Results In 100% CB Engraftment With Enhanced Myeloid Recovery Blood. 122: 298-298. DOI: 10.1182/Blood.V122.21.298.298 |
0.479 |
|
| 2013 |
Shih AH, Devlin SM, Dolezal EK, Knapp KM, Wang K, Sanford EM, Brennan T, Yelensky R, Nahas M, Otto GA, Lipson D, Stephens PJ, Miller V, van den Brink MR, Levine RL, et al. Comprehensive Mutational Profiling In Myelodysplastic Syndromes Treated With Decitabine and Tretinoin Blood. 122: 2791-2791. DOI: 10.1182/Blood.V122.21.2791.2791 |
0.336 |
|
| 2013 |
T Dang TO, Hilden P, Devlin SM, Rampal RK, Levine RL, Berman E, Klimek VM, Adel NG, Tallman MS. High-Dose Cytarabine Monotherapy Versus Intermediate Or High-Dose Cytarabine In Combination With Other Agents As Second-Line Salvage Therapy In Patients With Acute Myeloid Leukemia Who Did Not Respond To Initial Induction Therapy Blood. 122: 2695-2695. DOI: 10.1182/Blood.V122.21.2695.2695 |
0.442 |
|
| 2013 |
Stein EM, Hsu M, Goldrich A, Kishtagari A, Devlin SM, Tallman MS, Soff GA, Parameswaran R. Predicting Therapy-Related Acute Myeloid Leukemia By Routine Laboratory Values: An Analysis Of 126 Patients With Breast Cancer Referred For Bone Marrow Biopsy At Memorial Sloan-Kettering Cancer Center Blood. 122: 2661-2661. DOI: 10.1182/Blood.V122.21.2661.2661 |
0.315 |
|
| 2013 |
Zhou Q, Devlin S, Adel NG, Douer D. Outcomes Of Tyrosine Kinase Inhibitors In Combination With Various Treatments Regimens In Adult Patients With Philadelphia Chromosome Positive Acute Lymphocytic Leukemia Blood. 122: 2644-2644. DOI: 10.1182/Blood.V122.21.2644.2644 |
0.431 |
|
| 2013 |
Lee S, Devlin SM, Tallman MS, Douer D. A High Complete Remission Rate Can Be Achieved In Older Patients (Age ≥60) With Acute Lymphoblastic Leukemia Regardless Of Induction Intensities: Single-Institution Experience At Memorial Sloan-Kettering Cancer Center Blood. 122: 2638-2638. DOI: 10.1182/Blood.V122.21.2638.2638 |
0.363 |
|
| 2013 |
Maloy M, Devlin SM, Papadopoulos EB, Jakubowski AA. Stem Cell Transplant Versus Chemotherapy in Older Adults with Acute Myelogenous Leukemia In First Remission Blood. 122: 2146-2146. DOI: 10.1182/Blood.V122.21.2146.2146 |
0.471 |
|
| 2013 |
Koehne G, Devlin SM, Landau H, Hassoun H, Lesokhin A, Lendvai N, Chung DJ, Bravo C, Giralt S. T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation For Patients With Relapsed Multiple Myeloma and High-Risk Cytogenetics Permits Long-Lasting Remissions In The Absence Of Graft-Versus-Host Disease Blood. 122: 2115-2115. DOI: 10.1182/Blood.V122.21.2115.2115 |
0.464 |
|
| 2013 |
Hanash AM, Devlin SM, Maloy M, Knapp KM, Miller VA, Lipson D, Stephens PJ, Otto GA, Yelensky R, Nahas MK, Wang K, Levine RL, van den Brink MR, Jakubowski AA. Mutational Profiling Of Myeloid Malignancies For Prediction Of Disease Relapse Following Allogeneic Stem Cell Transplantation Blood. 122: 2096-2096. DOI: 10.1182/Blood.V122.21.2096.2096 |
0.409 |
|
| 2013 |
Ceberio I, Hilden P, Devlin SM, Malloy MA, Barker JN, Castro-Malaspina H, Jakubowski AA, Koehne G, Papadopoulos EB, Ponce DM, Sauter CS, Brink MRMvd, Young JW, O'Reilly RJ, Giralt S, et al. The Hematopoietic Cell Transplant-Co-Morbidity Index (HCT-CI) Predicts Outcomes After T Cell Depleted (TCD) Allogeneic HCT For AML and MDS Blood. 122: 2045-2045. DOI: 10.1182/Blood.V122.21.2045.2045 |
0.47 |
|
| 2013 |
Londono D, Devlin SM, Lesokhin A, Lendvai N, Hassoun H, Chung DJ, Koehne G, Jhanwar SC, Giralt SA, Landau H. Multiple Copies of MLL Is The Most Commonly Detected Cytogenetic Abnormality In Newly Diagnosed Multiple Myeloma and May Modify Disease Risk Blood. 122: 1910-1910. DOI: 10.1182/Blood.V122.21.1910.1910 |
0.38 |
|
| 2013 |
Ponce DM, Byam C, Devlin S, Lubin MN, Evans KL, Gonzales AMR, Sideroff M, Wells D, Giralt SA, Young JW, Papadopoulos EB, Kernan NA, Scaradavou A, Barker JN. Prospective Evaluation Of Alternative Donor Availability In 708 Patients: Improved Allograft Access With Enlarging CB Inventory For All Patients Including Racial and Ethnic Minorities Blood. 122: 162-162. DOI: 10.1182/Blood.V122.21.162.162 |
0.481 |
|
| 2013 |
Rampal RK, Devlin SM, Patel JP, Knapp KM, Patel M, Greenbowe JR, Young LE, He J, Wang K, Nahas MK, Yelensky R, Otto GA, Lipson D, Stephens PJ, Miller VA, et al. Integrated Genetic Profiling Of JAK2 Wildtype Chronic-Phase Myeloproliferative Neoplasms Blood. 122: 1588-1588. DOI: 10.1182/Blood.V122.21.1588.1588 |
0.306 |
|
| 2013 |
Hilden P, Mumaw C, Devlin S, Lubin MN, Evans KL, Prockop S, Scaradavou A, Kernan NA, Giralt SA, Brink MRMvd, Paczesny S, Barker JN. High Day 28 ST2 Biomarker Levels Predict Severe Day 100 Acute Graft-Versus-Host Disease and Day 180 Transplant-Related Mortality After Double-Unit Cord Blood Transplantation Blood. 122: 146-146. DOI: 10.1182/Blood.V122.21.146.146 |
0.483 |
|
| 2013 |
Devlin SM, Thomas EG, Emerson SS. Robustness of approaches to ROC curve modeling under misspecification of the underlying probability model Communications in Statistics - Theory and Methods. 42: 3655-3664. DOI: 10.1080/03610926.2011.636166 |
0.537 |
|
| 2013 |
Tamari R, Chung S, Devlin S, Jakubowski A, Papadopoulos E, Boulad F, Small T, Kernan N, Ponce D, Sauter C, Young J, Giralt S, O'Reilly R, Castro-Malaspina H. P-221 Characteristic of relapse after T cell depleted (TCD) allogeneic hematopoietic stem cell transplantation in patients with advanced MDS Leukemia Research. 37. DOI: 10.1016/S0145-2126(13)70268-6 |
0.484 |
|
| 2013 |
Tamari R, Chung S, Devlin S, Jakubowski A, Papadopoulos E, Perales MA, Ponce D, Goldberg J, Barker J, Sauter C, Koehne G, Young J, Giralt S, Castro-Malaspina H. P-219 T cell depleted (TCD) allogeneic hematopoietic stem cell transplant for older patients with advanced MDS and AML evolved from MDS Leukemia Research. 37. DOI: 10.1016/S0145-2126(13)70266-2 |
0.481 |
|
| 2013 |
Tonon J, Koehne G, Collins N, Malloy M, Chen X, Bleau S, Pessin M, Smith K, Maslak P, Devlin S, Giralt S, O'Reilly R, Jakubowski A, Meagher R. Final product composition after ex-vivo T-cell reduction: Miltenyi CliniMACS versus Baxter Isolex 300I in a large cohort of allogeneic trans-plant patients Cytotherapy. 15: S22-S23. DOI: 10.1016/J.Jcyt.2013.01.083 |
0.338 |
|
| 2013 |
Harnicar S, Ponce D, Gregornik D, Evans K, Zheng J, Devlin S, Barker JN. Association Between Mycophenolic Acid (MPA) Total Serum Trough Levels and Toxicity and Efficacy Outcomes in Cord Blood Transplantation (CBT) Recipients Biology of Blood and Marrow Transplantation. 19. DOI: 10.1016/J.Bbmt.2012.11.612 |
0.384 |
|
| 2013 |
Dahi P, Olson AL, Devlin S, Lubin M, Gonzales AM, Evans K, Scaradavou A, Kernan N, Small T, O'Reilly R, Giralt SA, Koehne G, Perales M, Ponce D, Papanicolaou Z, et al. Incidence, Nature, Risk Factors and Outcomes of Cytomegalovirus Infection After Double-Unit Cord Blood Transplantation Biology of Blood and Marrow Transplantation. 19. DOI: 10.1016/J.Bbmt.2012.11.529 |
0.369 |
|
| 2013 |
Olson AL, Lehrman R, Devlin S, Maloy M, Castro-Malaspina H, Giralt SA, Goldberg J, O'Reilly R, Perales M, Papadopoulos E, Jakubowski AA. The Prognostic Significance of Peripheral Blood Mixed Chimerism After T-Cell Depleted Allogeneic Stem Cell Transplant Biology of Blood and Marrow Transplantation. 19. DOI: 10.1016/J.Bbmt.2012.11.440 |
0.441 |
|
| 2013 |
Morawa E, Zabor E, Maloy M, Devlin S, Giralt SA. The Management of Relapsed AML or MDS Following a T-Cell Depleted Allogeneic Stem Cell Transplant Biology of Blood and Marrow Transplantation. 19. DOI: 10.1016/J.Bbmt.2012.11.437 |
0.437 |
|
| 2013 |
Landau H, Fein D, Hassoun H, Bello C, Chou J, Devlin S, Giralt SA, Comenzo R. Long-Term Outcomes of Patients With Systemic Light Chain Amyloidosis (AL) Treated at Diagnosis With Risk-Adapted Stem Cell Transplant and Consolidation With Novel Agents Biology of Blood and Marrow Transplantation. 19. DOI: 10.1016/J.Bbmt.2012.11.298 |
0.412 |
|
| 2013 |
Wood K, Giralt SA, Koehne G, Chung D, Hassoun H, Lendvai N, Lesokhin A, Hoover E, Devlin S, Landau H. Fractionated Stem Cell Infusions for Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplant Biology of Blood and Marrow Transplantation. 19. DOI: 10.1016/J.Bbmt.2012.11.197 |
0.443 |
|
| 2013 |
Tamari R, Dahi P, Devlin S, Goldberg J, Paul PH, Matasar M, Maragulia J, Perales M, Moskowitz CH, Sauter CS. High Dose Therapy and Autologous Stem Cell Transplantation Results in Good Outcomes and Acceptable Toxicities in Elderly Patients with Non-Hodgkin's Lymphoma Biology of Blood and Marrow Transplantation. 19. DOI: 10.1016/J.Bbmt.2012.11.069 |
0.543 |
|
| 2013 |
Landau H, Hassoun H, Bello C, Chou J, Devlin S, Giralt SA, Comenzo R. Risk-Adapted Melphalan and Stem Cell Transplant for Systemic Light Chain Amyloidosis: A Single Institution Experience Biology of Blood and Marrow Transplantation. 19. DOI: 10.1016/J.Bbmt.2012.11.066 |
0.329 |
|
| 2013 |
Olson AL, Dahi P, Zheng J, Devlin S, Lubin M, Gonzales AM, Giralt SA, Ponce D, Kernan N, Scaradavou A, Papanicolaou G, Barker JN. Human Herpesvirus-6 (HHV-6) Viremia Is Frequent but the Incidence of Encephalitis Is Low in Double-Unit Cord Blood Transplantation (CBT) Recipients Transplanted without ATG Biology of Blood and Marrow Transplantation. 19. DOI: 10.1016/J.Bbmt.2012.11.056 |
0.421 |
|
| 2012 |
Perales MA, Goldberg JD, Yuan J, Koehne G, Lechner L, Papadopoulos EB, Young JW, Jakubowski AA, Zaidi B, Gallardo H, Liu C, Rasalan T, Wolchok JD, Croughs T, Morre M, ... Devlin SM, et al. Recombinant human interleukin-7 (CYT107) promotes T-cell recovery after allogeneic stem cell transplantation. Blood. 120: 4882-91. PMID 23012326 DOI: 10.1182/Blood-2012-06-437236 |
0.414 |
|
| 2012 |
Klimek VM, Dolezal EK, Tees MT, Devlin SM, Stein K, Romero A, Nimer SD. Efficacy of hypomethylating agents in therapy-related myelodysplastic syndromes. Leukemia Research. 36: 1093-7. PMID 22608310 DOI: 10.1016/J.Leukres.2012.04.025 |
0.35 |
|
| 2012 |
Park JH, Devlin S, Tallman MS, Douer D. Outcomes of patients older than 60 years with acute lymphoblastic leukemia: Survey from the Surveillance, Epidemiology, and End Results (SEER) program. Journal of Clinical Oncology. 30: 6532-6532. DOI: 10.1200/Jco.2012.30.15_Suppl.6532 |
0.33 |
|
| 2012 |
Lendvai N, Landau H, Lesokhin A, Tsakos I, Koehne G, Chung D, Devlin S, Hassoun H, Giralt SA. Phase II Study of Infusional Carfilzomib in Patients with Relapsed or Refractory Multiple Myeloma Blood. 120: 947-947. DOI: 10.1182/Blood.V120.21.947.947 |
0.405 |
|
| 2012 |
Olson AL, Dahi PB, Zheng J, Devlin S, Lubin MN, Gonzales AM, Giralt SA, Ponce DM, Kernan NA, Scaradavou A, Papanicolaou G, Barker JN. HHV-6 Viremia Is Frequent but the Incidence of Encephalitis Is Low in Double-Unit Cord Blood Transplant Recipients Transplanted without ATG Blood. 120: 459-459. DOI: 10.1182/Blood.V120.21.459.459 |
0.512 |
|
| 2012 |
Wood K, Giralt SA, Koehne G, Chung D, Lendvai N, Hassoun H, Lesokhin A, Hoover E, Devlin S, Landau H. Fractionated Stem Cell Infusions for Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplant Blood. 120: 4550-4550. DOI: 10.1182/Blood.V120.21.4550.4550 |
0.465 |
|
| 2012 |
Rodriguez M, Adel NG, Devlin S, Giralt SA, Landau H. Cryotherapy Reduces Mucositis in Multiple Myeloma Patients Receiving High-Dose Melphalan Conditioning Prior to Autologous Stem Cell Transplantation Blood. 120: 4265-4265. DOI: 10.1182/Blood.V120.21.4265.4265 |
0.469 |
|
| 2012 |
Izaskun C, Devlin S, Sauter CS, Barker JN, Castro-Malaspina H, Giralt SA, Ponce DM, Lechner L, Gonzales AMR, Goldberg JD, Perales M. Sirolimus, Tacrolimus and Low-Dose Methotrexate Based Graft-Versus-Host Disease (GVHD) Prophylaxis After Non-Ablative or Reduced Intensity Conditioning in Related and Unrelated Donor Allogeneic Stem Cell Transplantation: Decreased Severe Early aGVHD but Persistence of Late Acute Gvhd Blood. 120: 4194-4194. DOI: 10.1182/Blood.V120.21.4194.4194 |
0.532 |
|
| 2012 |
Olson AL, Barker JN, Castro-Malaspina H, Devlin S, Giralt SA, Goldberg JD, Lehrman R, Maloy M, O'Reilly RJ, Perales M, Papadopoulos EB, Jakubowski AA. Bone Marrow Mixed Chimerism Is a Risk Factor for Relapse After T-Cell Depleted Allogeneic Stem Cell Transplant Blood. 120: 4145-4145. DOI: 10.1182/Blood.V120.21.4145.4145 |
0.55 |
|
| 2012 |
Zamarin D, Devlin S, Arcila M, Giralt SA, Landau H, Lesokhin A, Lendvai N, Chung D, Chimento D, Babu D, Hassoun H. Reactive Polyclonal Gammopathy Associated with Polyclonal Plasmacytosis Is Common in Patients with Multiple Myeloma Receiving Prolonged Lenalidomide Therapy: A Retrospective Study of 104 Patients Blood. 120: 4033-4033. DOI: 10.1182/Blood.V120.21.4033.4033 |
0.405 |
|
| 2012 |
Klimek VM, Dolezal EK, Jurcic JG, Devlin S, Zikaras K, Park JH, Rosenblat TL, Nimer S. Phase 2 Study of Decitabine in Combination with Tretinoin in Myelodysplastic Syndromes and Acute Myelogenous Leukemia: Interim Results Blood. 120: 3815-3815. DOI: 10.1182/Blood.V120.21.3815.3815 |
0.354 |
|
| 2012 |
Comenzo RL, Fein DE, Hassoun H, Bello C, Chou JF, Devlin S, Giralt SA, Landau H. Long-Term Outcomes of Patients with Systemic Light Chain Amyloidosis (AL) Treated At Diagnosis with Risk-Adapted Stem Cell Transplant and Consolidation with Novel Agents. Blood. 120: 3150-3150. DOI: 10.1182/Blood.V120.21.3150.3150 |
0.418 |
|
| 2012 |
Tamari R, Ramnath S, Kuk D, Sauter CS, Ponce DM, Devlin S, Young JW, Giralt S, Castro-Malaspina HR. Poor Graft Function in Recipients of T Cell Depleted (TCD) Allogeneic Hematopoietic Stem Cell Transplants (HSCT) Is Mostly Related to Viral Infections and Anti-Viral Therapy. Blood. 120: 3147-3147. DOI: 10.1182/Blood.V120.21.3147.3147 |
0.519 |
|
| 2012 |
Landau H, Fein DE, Hassoun H, Bello C, Chou JF, Devlin S, Giralt S, Comenzo RL. Risk-Adapted Melphalan and Stem Cell Transplant for Systemic Light Chain Amyloidosis: A Single Institution Experience. Blood. 120: 3109-3109. DOI: 10.1182/Blood.V120.21.3109.3109 |
0.465 |
|
| 2012 |
Gardner JR, Devlin S, Knapp K, Bauli F, Lamanna N, Frattini MG, Brentjens RJ, Maslak PG, Jurcic JG, Weiss M, Scheinberg DA, Heaney M. Aerobic Glycolysis Predicts Outcome in Early Chronic Lymphocytic Leukemia. Blood. 120: 2482-2482. DOI: 10.1182/Blood.V120.21.2482.2482 |
0.382 |
|
| 2012 |
Chung SS, Goldberg JD, Papadopoulos EB, Jakubowski AA, Devlin S, Boulad F, Perales M, Kernan NA, Ponce DM, Small TN, Koehne G, Barker JN, O'Reilly RJ, Giralt SA, van den Brink MR, et al. Unrelated Donor T-Cell Depleted (TCD) Hematopoietic Stem Cell Transplantation (HSCT) for Patients with Advanced Myelodysplastic Syndromes (MDS): The MSKCC Experience Blood. 120: 1996-1996. DOI: 10.1182/Blood.V120.21.1996.1996 |
0.498 |
|
| 2012 |
Tamari R, Sheetal SR, Kuk D, Papadopoulos EB, Jakubowski AA, Boulad F, Small TN, Kernan NA, Perales MA, Koehne G, Ponce DM, Devlin S, Goldberg JD, Young JW, Giralt SA, et al. A Phase II Trial of Peri-Transplant Palifermin with Busulfan, Melphalan and Fludarabine Followed by T-Cell Depleted Hematopoietic Stem Cell Transplants in Patients with Advanced Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Evolved From MDS Blood. 120: 1935-1935. DOI: 10.1182/Blood.V120.21.1935.1935 |
0.539 |
|
| 2008 |
Asfaha S, Geddes M, Leung Y, Storek J, Devlin SM, Jones J, Kaplan GG, Heatherington JA, Hilsden RJ, Beck PL, Panaccione R. T1156 Risk-Aversion Profile of Crohn's Patients: A Feasibility Study for Stem Cell Transplantation Gastroenterology. 134: A-496. DOI: 10.1016/S0016-5085(08)62315-X |
0.35 |
|
| Show low-probability matches. |